


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07K 5/06, 5/08, 5/10, 5/02, A61K 38/04	A1	(11) International Publication Number: WO 96/30396
		(43) International Publication Date: 3 October 1996 (03.10.96)

(21) International Application Number: PCT/US96/04115	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 25 March 1996 (25.03.96)	
(30) Priority Data: 06/410,518 24 March 1995 (24.03.95) US 08/549,006 27 October 1995 (27.10.95) US	
(71) Applicant (for all designated States except US): MOLECUMETICS LTD. (US/US); Suite 400, 2023 120th Avenue N.E, Bellevue, WA 98005-2189 (US).	
(72) Inventor; and	
(75) Inventor/Applicant (for US only): KAHN, Michael (US/US); 10916 80th Place N.E, Kirkland, WA 98034 (US).	
(74) Agents: HERMANN, Karl, R. et al.; Seed and Berry L.L.P., 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).	

(54) Title: β -SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS

(57) Abstract

There are disclosed β -sheet mimetics and methods relating to the same for imparting or stabilizing the β -sheet structure of a peptide, protein or molecule. In one aspect, the β -sheet mimetics are covalently attached at the end or within the length of the peptide or protein. The β -sheet mimetics have utility as protease inhibitors generally, including activity as serine protease inhibitors such as thrombin, elastase and Factor X.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Bahamas	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KZ	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sierra Leone
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroun	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SS	Switzerland
CZ	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	US	United Kingdom
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

6. Application No.
PCT/US 96/04115

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K5/08 C07K5/08 C07K5/10 C07K5/02 A61K38/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevance to claim No.
A	<p>TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 49, no. 17, 23 April 1993, OXFORD GB, pages 3577-3592, XP002008589 U NAGAI ET AL.: "Bicyclic turned dipeptide (BTD) as a beta-turn mimetic; its design, synthesis and incorporation into bioactive peptides" see the whole document ---</p> <p style="text-align: center;">-/-</p>	1-46

Further documents are listed in the continuation of box C.

Patent family members are listed on annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
- *'O' document referring to an oral document, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

- *'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *'Z' document member of the same patent family

1

Date of the actual completion of the international search 16 July 1996	Date of mailing of the international search report 29. 07. 96
Name and mailing address of the ISA European Patent Office, P.B. 3818 Potsdamer 2 NL - 1220 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl. Fax (+ 31-70) 340-2016	Authorized officer Masturzo, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/04115

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **Claims Nos.:**
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 37-46 refer to a method of treatment of the human body. The search was carried out and based on the alleged effects of the products.
2. **Claims Nos.:**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. **Claims Nos.:**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Is National Application No
PCT/US 96/04115

C/(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TETRAHEDRON LETTERS, vol. 36, no. 4, 23 January 1995, OXFORD GB, pages 625-628, XP002008590 L COLOMBO ET AL.: "Conformationally constrained dipeptides; synthesis of 7,5 and 6,5-fused bicyclic lactams by stereoselective radical cyclization" see the whole document ---</p>	1-46
P,X	<p>JOURNAL OF ORGANIC CHEMISTRY, vol. 61, no. 4, 23 February 1996, EASTON US, pages 1198-1204, XP002008591 U SLOMCZYNSKA ET AL.: "Electrochemical cyclization of dipeptides to form novel bicyclic, reverse turn peptidomimetics. 2. Synthesis and conformational analysis of 6,5-bicyclic systems" see the whole document ---</p>	1-46
A	<p>CHEMICAL ABSTRACTS, vol. 117, no. 13, 28 September 1992 Columbus, Ohio, US; abstract no. 131548s, J E BALDWIN ET AL.: "Synthesis of a bicyclic gamma-lactam dipeptide analog" page 786; XP002008592 see abstract & HETEROCYCLES, vol. 34, no. 5, May 1992, AMSTERDAM NL, pages 983-986. -----</p>	1-46

Description

**β-SHEET MIMETICS AND USE THEREOF
AS PROTEASE INHIBITORS**

5

Cross-Reference to Prior Application

This application is a continuation-in-part of U.S. Patent Application No. 08/549,006, filed October 27, 1995; which is a continuation-in-part of U.S. Patent 10 Application No. 08/410,518, filed March 24, 1995.

Technical Field

This invention relates generally to β-sheet mimetics and, more specifically, to β-sheet mimetics for 15 use as protease inhibitors.

Background of the Invention

The β-sheet conformation (also referred to as a β-strand conformation) is a secondary structure present in 20 many polypeptides. The β-sheet conformation is nearly fully extended, with axial distances between adjacent amino acids of approximately 3.5 Å. The β-sheet is stabilized by hydrogen bonds between NH and CO groups in different polypeptides strands. Additionally, the dipoles 25 of the peptide bonds alternate along the strands which imparts intrinsic stability to the β-sheet. The adjacent strands in the β-sheet can run in the same direction (i.e., a parallel β-sheet) or in opposite directions (i.e., an antiparallel β-sheet). Although the two forms 30 differ slightly in dihedral angles, both are sterically favorable. The extended conformation of the β-sheet conformation results in the amino acid side chains protruding on alternating faces of the β-sheet.

The importance of β -sheets in peptides and proteins is well established (e.g., Richardson, *Nature* 268:495-499, 1977; Halverson et al., *J. Am. Chem. Soc.* 113:6701-6704, 1991; Zhang, *J. Biol. Chem.* 266:15591-15596, 1991; Madden et al., *Nature* 353:321-325, 1991). The β -sheet is important in a number of biological recognition events, including the interaction between proteases and proteolytic substrates. Protease activity has been implicated in many disease states.

10 Cathepsin B is a lysosomal cysteine protease normally involved in proenzyme processing and protein turnover. Elevated levels of activity have been implicated in tumor metastasis (Sloane, B.F. et al., "Cathepsin B and its endogenous inhibitors: the role in 15 tumor malignancy," *Cancer Metastasis Rev.* 9:333-352, 1990), rheumatoid arthritis (Werb, Z. "Proteinases and matrix degradation," in *Textbook of Rheumatology*, Keller, W.N.; Harris, W.D.; Ruddy, S.; Sledge, C.S., Eds., 1989, W.B. Saunder Co., Philadelphia, PA, pp. 300-321), and 20 muscular dystrophy (Katunuma N. & Kominami E., "Abnormal expression of lysosomal cysteine proteinases in muscle wasting diseases," *Rev. Physiol. Biochem. Pharmacol.* 108:1-20, 1987).

25 Calpains are cytosolic or membrane bound Ca^{++} -activated proteases which are responsible for degradation of cytoskeletal proteins in response to changing calcium levels within the cell. They contribute to tissue degradation in arthritis and muscular dystrophy (see Wang K.K. & Yuen P.W., "Calpain inhibition: an overview of its 30 therapeutic potential," *Trends Pharmacol. Sci.* 15:412-419, 1994).

Interleukin Converting Enzyme (ICE) cleaves pro-IL-1 beta to IL-1 beta, a key mediator of inflammation, and therefore inhibitors of ICE may prove useful in the

treatment of arthritis (see, e.g., Miller B.E. et al., "Inhibition of mature IL-1 beta production in murine macrophages and a murine model of inflammation by WIN 67694, an inhibitor of IL-1 beta converting enzyme," *J. Immunol.* 154:1331-1338, 1995). ICE or ICE-like proteases may also function in apoptosis (programmed cell death) and therefore play roles in cancer, AIDS, Alzheimer's disease, and other diseases in which deregulated apoptosis is involved (see Barr, P.J.; Tomei, L.D., "Apoptosis and its 10 Role in Human Disease," *Biotechnol.* 12:487-493, 1994).

HIV protease plays a key role in the life cycle of HIV, the AIDS virus. In the final steps of viral maturation it cleaves polyprotein precursors to the functional enzymes and structural proteins of the virion 15 core. HIV protease inhibitors were quickly identified as an excellent therapeutic target for AIDS (see Huff, J.R., "HIV protease: a novel chemotherapeutic target for AIDS," *J. Med. Chem.* 34:2305-2314) and have already proven useful in its treatment as evidenced by the recent FDA approval 20 of ritonavir, Crixivan, and saquinavir.

Angiotensin converting enzyme (ACE) is part of the renin-angiotensin system which plays a central role in the regulation of blood pressure. ACE cleaves angiotensin I to the octapeptide angiotensin II, a potent pressor 25 agent due to its vasoconstrictor activity. Inhibition of ACE has proved therapeutically useful in the treatment of hypertension. (Williams, G.H., "Converting-enzyme inhibitors in the treatment of hypertension," *N. Engl. J. Med.* 319:1517-1525, 1989.

30 Collagenases cleave collagen, the major constituent of the extracellular matrix (e.g., connective tissue, skin, blood vessels). Elevated collagenase activity contributes to arthritis (Krane S.M. et al., "Mechanisms of matrix degradation in rheumatoid

arthritis," *Ann. N.Y. Acad. Sci.* 580:340-354, 1990.), tumor metastasis (Flug M. & Kopf-Maier P., "The basement membrane and its involvement in carcinoma cell invasion," *Acta Anat. Basel* 152:69-84, 1995), and other diseases 5 involving the degradation of connective tissue.

Trypsin-like serine proteases form a large and highly selective family of enzymes involved in hemostasis/coagulation (Davie, E.W. and K. Fujikawa, "Basic mechanisms in blood coagulation," *Ann. Rev.* 799-10 829, 1975) and complement activation (Muller-Eberhard, H.J., "Complement," *Ann. Rev. Biochem.* 44:697-724, 1975). Sequencing of these proteases has shown the presence of a homologous trypsin-like core with amino acid insertions that modify specificity and which are generally 15 responsible for interactions with other macromolecular components (Magnusson et al., "Proteolysis and Physiological Regulation," *Miami Winter Symposia* 11:203-239, 1976).

Thrombin, a trypsin-like serine protease, acts 20 to provide limited proteolysis, both in the generation of fibrin from fibrinogen and the activation of the platelet receptor, and thus plays a critical role in thrombosis and hemostasis (Mann, K.G., "The assembly of blood clotting complexes on membranes," *Trends Biochem. Sci.* 12:229-233, 25 1987). Thrombin exhibits remarkable specificity in the removal of fibrinopeptides A and B of fibrinogen through the selective cleavage of only two Arg-Gly bonds of the one-hundred and eighty-one Arg- or Lys-Xaa sequences in fibrinogen (Blomback, H., *Blood Clotting Enzymology*, 30 Seeger, W.H. (ed.), Academic Press, New York, 1967, pp. 143-215).

Many significant disease states are related to abnormal hemostasis, including acute coronary syndromes. Aspirin and heparin are widely used in the treatment of

patients with acute coronary syndromes. However, these agents have several intrinsic limitations. For example, thrombosis complicating the rupture of atherosclerotic plaque tends to be a thrombin-mediated, platelet-dependent process that is relatively resistant to inhibition by aspirin and heparin (Fuster et al., "The pathogenesis of coronary artery disease and the acute coronary syndromes," *N. Engl. J. Med.* 326:242-50, 1992).


Thrombin inhibitors prevent thrombus formation at sites of vascular injury *in vivo*. Furthermore, since thrombin is also a potent growth factor which initiates smooth muscle cell proliferation at sites of mechanical injury in the coronary artery, inhibitors block this proliferative smooth muscle cell response and reduce restenosis. Thrombin inhibitors would also induce the inflammatory response in vascular wall cells (Harker et al., *Am. J. Cardiol* 75:12B-16B, 1995).

In view of the important biological role played by the β -sheet, there is a need in the art for compounds which can stabilize the intrinsic β -sheet structure of a naturally occurring or synthetic peptide, protein or molecule. There is also a need in the art for making stable β -sheet structures, as well as the use of such stabilized structures to effect or modify biological recognition events which involve β -sheet structures. The present invention fulfills these needs and provides further related advantages.

Summary of the Invention

Briefly stated, the present invention is directed to β -sheet mimetics and, more specifically, to β -sheet mimetics which stabilize the β -strand structure of a natural or synthetic peptide, protein or molecule.

In one aspect of this invention, β -sheet mimetics are disclosed including a bicyclic ring system, wherein the β -sheet mimetic has the general structure (I):




5

(I)

and pharmaceutically acceptable salts thereof, wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; A is selected from -C(=O)-, -(CH₂)₁₋₄-, -C(=O)(CH₂)₁₋₃-, -(CH₂)₁₋₂O- and -(CH₂)₁₋₂S-; B is selected from N and CH; C is selected from -C(=O)-, -(CH₂)₁₋₃-, -O-, -S-, -O-(CH₂)₁₋₂- and -S(CH₂)₁₋₂-; Y and Z represent the remainder of the molecule; and any two adjacent CH groups of the bicyclic ring may form a double bond; with the provisos that (i) R₁ is an amino acid side chain moiety or derivative thereof other than hydrogen, (ii) when R₁ is benzyl, R₂ and R₃ are both hydrogen, A is -CH₂CH₂- and B is CH, then C is not -CH₂-; (iii) when R₁ is methyl, R₂ and R₃ are both hydrogen, A is -CH₂O- and B is CH, then C is not -CH₂-; and (iv) when R₁ is benzyl, R₂ and R₃ are both hydrogen, A is -CH₂- and B is CH, then C is not -S-.


In one embodiment of structure (I) above, β -sheet mimetics are disclosed having the following structure (II):



(II)


wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; A is selected from -C(=O)-, -(CH₂)₁₋₄- and -C(=O)(CH₂)₁₋₃-; B is selected from N and CH; C is selected from -C(=O)- and -(CH₂)₁₋₃-; Y and Z represent the remainder of the molecule and the bicyclic ring system is saturated (i.e., contains 10 no double bonds between adjacent CH groups of the bicyclic ring system).

In an embodiment of structure (II) where B is CH and R₃ is hydrogen, β -sheet mimetics are disclosed having the following structures (III), (IV) and (V):




15

(III)




(IV)




(V)

wherein R₁ and R₂ are independently selected from amino acid side chain moieties and derivatives thereof; n is an integer from 1 to 4; p is an integer from 1 to 3; and Y and Z represent the remainder of the molecule.


In an embodiment of structure (II) where B is N and R₃ is hydrogen, β -sheet mimetics are disclosed having the following structures (VI), (VII) and (VIII):



(VI)




(VII)




(VIII)

wherein R₁ and R₂ are independently selected from amino acid side chain moieties and derivatives thereof; n is an integer from 1 to 4; p is an integer from 1 to 3; and Y and Z represent the remainder of the molecule.


In preferred embodiments of this aspect of the invention, β-sheet mimetics are disclosed having the following structures (IX), (X) and (XI):



(IX)




(X)



(XI)

wherein R₁ and R₂ are independently selected from amino acid side chain moieties and derivatives thereof; n is an integer from 1 to 4; and Y and Z represent the remainder of the molecule.

In a further preferred embodiment of this aspect of the invention, a β-sheet mimetic is disclosed of structure (X) above wherein n is 2, and having the following structure (Xa):




(Xa)

wherein R₁ and R₂ are independently selected from amino acid side chain moieties and derivatives thereof; and Y and Z represent the remainder of the molecule.

In another embodiment of structure (I) above, β -sheet mimetics are disclosed having the following structure (XII):


10



(XII)

wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; A is selected from -(CH₂)₁₋₄-, -(CH₂)₁₋₂O- and -(CH₂)₁₋₂S-, C is selected from -(CH₂)₁₋₃-, -O-, -S-, -O(CH₂)₁₋₂- and -S(CH₂)₁₋₂-; Y and Z represent the remainder of the molecule and the bicyclic ring system is saturated.


20 In an embodiment of structure (XII) where A is -(CH₂)₁₋₄-, β -sheet mimetics are disclosed having the following structure (XIII):




(XIII)

5 wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; n is an integer from 1 to 4; C is selected from -(CH₂)₁₋₃-, -O-, -S-, -O(CH₂)₁₋₂- and -S(CH₂)₁₋₂-; and Y and Z represent the remainder of the molecule.

10 In an embodiment of structure (XII) where A is -(CH₂)₁₋₂O- or -(CH₂)₁₋₂S-, β -sheet mimetics are disclosed having the following structures (XIV) and (XV):




15 (XIV)



(XV)

wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; m is an integer from 1 to 2; p is an integer from 1 to 3; and Y and Z represent the remainder of the molecule.

20 In an embodiment of structure (XII) where C is -(CH₂)₁₋₃-, β -sheet mimetics are disclosed having the following structure (XVI):





25 (XVI)

wherein R₁, R₂ and R₃ are independently selected from an amino acid side chain moiety and derivatives thereof; p is an integer from 1 to 3; A is selected from -(CH₂)₁₋₄-, 5 -(CH₂)₁₋₂O- and -(CH₂)₁₋₂S-; and Y and Z represent the remainder of the molecule.



In an embodiment of structure (XII) where C is -O- or -S-, β -sheet mimetics are disclosed having the following structures (XVII) and (XVIII):

10



15 wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; p is an integer from 1 to 3; and Y and Z represent the remainder of the molecule.

In an embodiment of structure (XII) where C is -C(CH₂)₁₋₂- or -S(CH₂)₁₋₂-, β -sheet mimetics are disclosed 20 having the following structures (XIX) and (XX):



25

wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; p is an

integer from 1 to 3; m is an integer from 1 to 2; and Y and Z represent the remainder of the molecule.

In a further aspect of the present invention, β -sheet modified peptides or proteins are disclosed wherein 5 a β -sheet mimetic of this invention is covalently attached to at least one amino acid of a naturally occurring or synthetic peptide or protein. In this embodiment, Y and/or Z in the above structures (I) through (XX) represent one or more amino acids of the peptide or 10 protein. In a related embodiment, a method for imparting and/or stabilizing a β -sheet structure of a natural or synthetic peptide or protein is disclosed. This method includes covalently attaching one or more β -sheet mimetics of this invention within, or to the end of, a peptide or 15 protein.

In yet a further embodiment, methods are disclosed for inhibiting a protease in a warm-blooded animal by administering to the animal an effective amount of a compound of this invention. Proteases include serine 20 proteases, such as thrombin, elastase and Factor X, as well as aspartic, cysteine and metallo proteases.

Other aspects of this invention will become apparent upon reference to the following detailed description.

25 Brief Description of the Drawings

Figure 1 is a plot showing the effect of various concentrations of structure (20b) on platelet deposition in a vascular graft.





Figure 2 is a plot showing the effect of various 30 concentrations of structure (39) on platelet deposition in a vascular graft.

Figure 3 is a plot showing the effect of various concentrations of structure (29b) on platelet deposition in a vascular graft.

5 Detailed Description of the Invention

As mentioned above, the β -sheet is an important structural component for many biological recognition events. The β -sheet mimetics of this invention serve to impart and/or stabilize the β -sheet structure of a natural 10 or synthetic peptide, protein or molecule, particularly with regard to conformational stability. In addition, the β -sheet mimetics of this invention are more resistant to proteolytic breakdown, thus rendering a peptide, protein or molecule containing the same more resistant to 15 degradation.

The β -sheet mimetics of this invention are generally represented by structure (I) above, as well as the more specific embodiments represented by structures (II) through (XX), and have stereochemistries represented 20 by structures (I') through (I''') below:



wherein R₁, R₂, R₃, A, B, C, Y and Z are as defined above. In other words, all stereoconformations of structure (I), as well as the more specific embodiments represented by structures (II) through (XX), are included within the 5 scope of this invention. For example, the β -sheet mimetics of this invention may be constructed to mimic the three-dimensional conformation of a β -sheet comprised of naturally occurring L-amino acids, as well as the structure of a β -sheet comprised of one or more D-amino 10 acids. In a preferred embodiment, the β -sheet mimetic has the stereoconformation of structure (I') or (I'').



As used in the context of this invention, the term "remainder of the molecule" (as represented by Y and Z in structures (I) through (XX) above) may be any 15 chemical moiety. For example, when the β -sheet mimetic is located within the length of a peptide or protein, Y and Z may represent amino acids of the peptide or protein. Alternatively, if two or more β -sheet mimetics are linked, the Y moiety of a first β -sheet mimetic may represent a 20 second β -sheet mimetic while, conversely, the Z moiety of the second β -sheet mimetic represents the first β -sheet mimetic. When the β -sheet mimetic is located at the end 25 of a peptide or protein, or when the β -sheet mimetic is not associated with a peptide or protein, Y and/or Z may represent a suitable terminating moiety. Representative terminating moieties for the Z moiety include, but are not limited to, -H, -OH, -R, -C(=O)R and -SO₂R (where R is a C₁-C₈ alkyl or aryl moiety), or may be a suitable 30 protecting group for protein synthesis, such as BOC, FMOC or CBZ (i.e., *tert*-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl, and benzyloxycarbonyl, respectively). Similarly, representative terminating moieties for the Y moiety include, but are not limited to, -H, -OH, -R, -NHOH, -NHNHR, -C(=O)OR, -C(=O)NHR, -CH₂Cl,

$-\text{CF}_3$, $-\text{C}_2\text{F}_5$, $-\text{C}(=\text{O})\text{CH}_2\text{N}_2^+$,
 $-\text{CH}(\text{O})\text{CHC}(=\text{O})\text{OR}$, $-\text{CH}(\text{O})\text{CHC}(=\text{O})\text{R}$ — (where R is a C1-C8
 alkyl or aryl moiety), or a heterocyclic moiety, such as
 5 pyridine, pyran, thiophan, pyrrole, furan, thiophene,
 thiazole, benzthiazole, oxazole, benzoxazole, imidazole
 and benzimidazole.

As used herein, the term "an amino acid side chain moiety" represents any amino acid side chain moiety present in naturally occurring proteins, including (but not limited to) the naturally occurring amino acid side chain moieties identified in Table 1 below. Other naturally occurring side chain moieties of this invention include (but are not limited to) the side chain moieties of 3,5-dibromotyrosine, 3,5-diiodotyrosine, hydroxylysine, 15 naphthylalanine, thienylalanine, γ -carboxyglutamate, phosphotyrosine, phosphoserine and glycosylated amino acids such as glycosylated serine, asparagine and threonine.

Table 1

<u>Amino Acid Side Chain Moiety</u>	<u>Amino Acid</u>
$-\text{H}$	Glycine
$-\text{CH}_3$	Alanine
$-\text{CH}(\text{CH}_3)_2$	Valine
$-\text{CH}_2\text{CH}(\text{CH}_3)_2$	Leucine
$-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$	Isoleucine
$-(\text{CH}_2)_4\text{NH}_3^+$	Lysine
$-(\text{CH}_2)_3\text{NHC}(\text{NH}_2)\text{NH}_2^+$	Arginine
$-\text{CH}_2-\text{C}(=\text{O})-\text{NH}-$	Histidine

<u>Amino Acid Side Chain Moiety</u>	<u>Amino Acid</u>
-CH ₂ COO ⁻	Aspartic acid
-CH ₂ CH ₂ COO ⁻	Glutamic acid
-CH ₂ CONH ₂	Asparagine
-CH ₂ CH ₂ CONH ₂	Glutamine
	Phenylalanine
	Tyrosine
	Tryptophan
-CH ₂ SH	Cysteine
-CH ₂ CH ₂ SCH ₃	Methionine
-CH ₂ OH	Serine
-CH(OH)CH ₃	Threonine

In addition to naturally occurring amino acid side chain moieties, the amino acid side chain moieties of the present invention also include various derivatives therecf. As used herein, a "derivative" of an amino acid side chain moiety includes all modifications and/or variations to naturally occurring amino acid side chain moieties. For example, the amino acid side chain moieties of alanine, valine, leucine, isoleucine and phenylalanine may generally be classified as lower chain alkyl, aryl or aralkyl moieties. Derivatives of amino acid side chain moieties include other straight chain or branched, cyclic or noncyclic, substituted or unsubstituted, saturated or unsaturated lower chain alkyl, aryl or aralkyl moieties.

As used herein, "lower chain alkyl moieties" contain from 1-12 carbon atoms, "lower chain aryl

moieties" contain from 6-12 carbon atoms, and "lower chain aralkyl moieties" contain from 7-12 carbon atoms. Thus, in one embodiment, the amino acid side chain derivative is selected from a C₁₋₁₂ alkyl, a C₆₋₁₂ aryl and a C₇₋₁₂ aralkyl, and in a more preferred embodiment, from a C₁₋₇ alkyl, a C₆₋₁₀ aryl and a C₇₋₁₁ aralkyl.

5 Amino acid side chain derivatives of this invention further include substituted derivatives of lower chain alkyl, aryl and aralkyl moieties, wherein the 10 substituent is selected from (but are not limited to) one or more of the following chemical moieties: -OH, -OR, -COOH, -COOR, -CONH₂, -NH₂, -NHR, -NRR, -SH, -SR, -SO₂R, -SO₂H, -SOR and halogen (including F, Cl, Br and I), 15 wherein each occurrence of R is independently selected from a lower chain alkyl, aryl or aralkyl moiety. Moreover, cyclic lower chain alkyl, aryl and aralkyl moieties of this invention include naphthalene, as well as heterocyclic compounds such as thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, 20 pyrrolidine, pyridine, pyrimidine, purine, quinoline, isoquinoline and carbazole. Amino acid side chain derivatives further include heteroalkyl derivatives of the alkyl portion of the lower chain alkyl and aralkyl moieties, including (but not limited to) alkyl and aralkyl 25 phosphonates and silanes.

Bicyclic lactams are known in the art. See, e.g., Columbo, L. et al., *Tet. Lett.* 36(4):525-628, 1995; Baldwin, J.E. et al., *Heterocycles* 34(5):903-906, 1992; and Slomczynska, U. et al., *J. Org. Chem.* 51:1198-1204, 30 1996. However, the bicyclic lactams of the invention are not disclosed in these references.


As mentioned above, the β -sheet mimetics of this invention serve to impart and/or stabilize the β -sheet structure of a protein, peptide or molecule. The β -sheet

mimetic may be positioned at either the C-terminus or N-terminus of the protein, peptide or molecule, or it may be located within the protein, peptide or molecule itself. In addition, more than one β -sheet mimetic of the present invention may be incorporated in a protein, peptide or molecule.


The β -sheet mimetics of this invention may be synthesized by a number of reaction schemes. For example, the various embodiments of structure (I) may be synthesized according to the following reaction schemes (1) through (17).

Reaction Scheme (1)

Structure (III) and representative compounds thereof having structure (IIIA) can be synthesized by the following reaction schemes:




19




Reaction Scheme (2)

Structure (IV) can be synthesized by the following reaction scheme:




Reaction Scheme (3)

Representative compounds of structure (V) having structure (Va) can be synthesized by the following reaction scheme, where structure (Ia) in scheme (3) is a representative structure of the invention having a double bond in the bicyclic ring system:




In addition, representative compounds of structure (V) having structure (Vb) may be synthesized by the following reaction scheme, and when A of structure (II) is $-\text{C}(=\text{O})(\text{CH}_2)_{1-3}-$, a related compound (designated 5 (IIa) below) can be synthesized by the following reaction scheme:



Reaction Scheme (4)

Representative compounds of structure (VI) having structures (VIa) and (VIb) below, wherein R₃ is hydrogen, can be synthesized by the following reaction scheme (see Holmes and Neel, *Tet. Lett.* 31:5567-70, 1990):




Representative compounds of structure (II) wherein R₃ is an amino acid side chain moiety or derivative thereof may also be prepared according to the above scheme (4).

Reaction Scheme (5)


Representative compounds of structure (VII)
having structure (VIIa) can be synthesized by the
following reaction scheme:

5



Reaction Scheme (6)


Structure (VIII) can be synthesized by the following reaction scheme:



5


Reaction Scheme (7)

Representative compounds of structure (IX) having structures (IXa) and (IXb) shown below, can be synthesized by the following reaction scheme:



Reaction Scheme (8)


Representative compounds of structure (X) having 5 structures (Xb) and (Xc) can be synthesized by the following reaction scheme (see Juncheim & Sigmund, *J. Org. Chem.* 52:4007-4013, 1987):



10


Reaction Scheme (9)

Structure (XI) may be synthesized by the following reaction scheme (see Perkin, *J. Chem. Soc. Perk. Trans. I*:155-164, 1984):




Reaction Scheme (10)

Structure (XIII) may be synthesized by the following reaction scheme:




Reaction Scheme (11)

Structures (XIV) and (XV) may be synthesized by the following reaction scheme:




Reaction Scheme (12)


Structure (XVI) may be synthesized by the following reaction scheme:



Reaction Scheme (13)


Structures (XVII) and (XVIII) may be synthesized by the following reaction scheme:






Reaction Scheme (14)


Structures (XIX) and (XX) may be synthesized by the following reaction scheme:






According to the definition of structure (I) above, the bicyclic ring system may contain adjacent CH groups (i.e., the bicyclic ring system may be formed, at least in part, by a -CH-CH- group). Compounds wherein such a -CH-CH- group is replaced with a -C=C- are also included within the scope of structure (I) (i.e., any two adjacent CH groups of the bicyclic ring may together form a double bond). It should be noted that R₁ according to the definition of structure (I) is a moiety other than hydrogen. Inspection of structure (I) indicates that the bicyclic ring atom to which R₁ is bonded may not be part of a carbon-carbon double bond according to structure (I) of the invention. However, R₂ and R₃ may be hydrogen, and thus the bicyclic ring atoms to which R₂ and/or R₃ are bonded may form part of a carbon-carbon double bond in compounds of structure (I).


Reaction Schemes (15), (16) and (17) illustrate synthetic methodology for preparing representative compounds of structure (I) wherein the bicyclic ring system is formed in part by a -C=C- group.

Reaction Scheme (15)


5

Reaction Scheme (16)


10

Reaction Scheme (17)


In β -sheet mimetics of the invention, preferred 5 Y groups have the structure:



where a preferred stereochemistry is:




Preferred R₄ groups are organoamine moieties having from about 2 to about 10 carbon atoms and at least one nitrogen atom. Suitable organoamine moieties have the chemical formula C₂₋₁₀H₄₋₂₀N₁₋₆O₀₋₂; and preferably have the 5 chemical formula C₃₋₇H₇₋₁₄N₁₋₄O₀₋₁. Exemplary organoamine moieties of the invention are:




In the above structure, R₅ is selected from (a) 10 alkyl of 1 to about 12 carbon atoms, optionally substituted with 1-4 of halide, C₁-alkoxy and nitro, (b) -C(=O)NH-C₁-alkyl, wherein the alkyl group is optionally substituted with halide or C₁-alkoxy, (c) -C(=O)NH-C₁₋₁₀aralkyl where the aryl group may be optionally 15 substituted with up to five groups independently selected from nitro, halide, -NH-(C=O)C₁-alkyl, -NH-(C=O)C₆₋₁₀aryl, C₁-alkyl and C₁-alkoxy, and (d) monocyclic and bicyclic heteroaryl of 4 to about 11 ring atoms, where the ring atoms are selected from carbon and the heteroatoms oxygen, 20 nitrogen and sulfur, and where the heteroaryl ring may be optionally substituted with up to about 4 of halide, C₁-alkyl, C₁-alkoxy, -C(=O)NH-C₁-alkyl, -C(=O)NH-C₆₋₁₀aryl, amino, -C(=O)OC₁-alkyl and -C(=O)OC₆₋₁₀aryl.

Preferred R₅ groups are:


25




wherein R₆ is hydrogen, nitro, halide, NH-C(=O)-C₁-alkyl, NH-C(=O)-C₆₋₁₀aryl, C₁-C₅alkyl and C₁-C₅alkoxy;



wherein X is halide;



wherein E is -O-, -NH- or -S- and R₇ and R₈ are 5 independently selected from hydrogen, C₁-alkyl, -C(=O)OC₁-alkyl, -C(=O)OC₆₋₁₀aryl, -C(=O)NHC₁-alkyl and -C(=O)NHC₆₋₁₀aryl; and



wherein E and R₆ are as defined previously.


10 The β -sheet mimetics of the present invention may be used in standard peptide synthesis protocols, including automated solid phase peptide synthesis. Peptide synthesis is a stepwise process where a peptide is formed by elongation of the peptide chain through the 15 stepwise addition of single amino acids. Amino acids are linked to the peptide chain through the formation of a peptide (amide) bond. The peptide link is formed by coupling the amino group of the peptide to the carboxylic acid group of the amino acid. The peptide is thus 20 synthesized from the carboxyl terminus to the amino terminus. The individual steps of amino acid addition are repeated until a peptide (or protein) of desired length and amino acid sequence is synthesized.




To accomplish peptide (or protein or molecule) 25 synthesis as described above, the amino group of the amino acid to be added to the peptide should not interfere with peptide bond formation between the amino acid and the peptide (i.e., the coupling of the amino acid's carboxyl group to the amino group of the peptide). To prevent such

interference, the amino groups of the amino acids used in peptide synthesis are protected with suitable protecting groups. Typical amino protecting groups include, for example, BOC and Fmoc groups. Accordingly, in one 5 embodiment of the present invention, the β -sheet mimetics of the present invention bear a free carboxylic acid group and a protected amino group, and are thus suitable for incorporation into a peptide by standard synthetic techniques.



10 The β -sheet mimetics of this invention have broad utility in naturally occurring or synthetic peptides, proteins and molecules. For example, the β -sheet mimetics disclosed herein have activity as 15 inhibitors of the large family of trypsin-like serine proteases, including those preferring arginine or lysine as a P' substituent. These enzymes are involved in blood coagulation, and include (but are not limited to) Factor VIIa, Factor IXa, Factor Xa, thrombin, kallikrein, 20 urokinase (which is also involved in cancer metastasis) and plasmin. Thus, the ability to selectively inhibit these enzymes has wide utility in therapeutic applications involving cardiovascular disease and oncology. To this end, the following β -sheet mimetics can be synthesized on solid support (e.g., PAM resin):

25








5



10





In the above β -sheet mimetics, L is an optional linker.

5 The β -sheet mimetics may then be cleaved from the solid support by, for example, aminolysis, and screened as competitive substrates against appropriate agents, such as the chromogenic substrate BAPNA (benzyoylarginine paranitroanalide) (see Eichler and 10 Houghten, *Biochemistry* 32:11035-11041, 1993) (incorporated herein by reference). Alternatively, by employing a suitable linker moiety, such screening may be performed while the β -sheet mimetics are still attached to the solid support.


15 Once a substrate is selected by the above kinetic analysis, the β -sheet mimetic may be converted into a protease inhibitor by modifications to the C-terminal - that is, by modification to the Y moiety. For example, the terminal Y moiety may be replaced with 20 -CH₂Cl, -CF₃, -H, or -C(O)NHR. Appropriate R moieties may be selected using a library of substrates, or using a library of inhibitors generated using a modification of the procedure of Wasserman and Ho (J. Org. Chem. 59:4364-4366, 1994) (incorporated herein by reference).

25 Libraries of compounds containing β -strand templates may be constructed to determine the optimal sequence for substrate recognition or binding. Representative strategies to use such libraries are discussed below.

30 A representative β -sheet mimetic substrate library may be constructed as follows. It should be


understood that the following is exemplary of methodology that may be used to prepare a β -sheet mimetic substrate library, and that other libraries may be prepared in an analogous manner.

5 In a first step, a library of the following
type:



may be constructed on a solid support (PEGA resin, Meldal, M. Tetrahedron Lett. 33:3077-80, 1992; controlled pore glass, Singh et al., J. Med. Chem. 38:217-19, 1995). The solid support may then be placed in a dialysis bag (Bednarski et al., J. Am. Chem. Soc. 109:1283-5, 1987) with the enzyme (e.g., a protease) in an appropriate buffer. The bag is then placed in a beaker with bulk buffer. The enzymatic reaction is monitored as a function of time by HPLC and materials cleaved from the polymer are analyzed by MS/MS. This strategy provides information concerning the best substrates for a particular enzyme/protease.


25 The synthesis of the above β -sheet mimetic is illustrated by the retrosynthetic procedure shown next:



The complexity of the library generated by this technique is $(R_1)(R_2)(R)(Y)$. Assuming R_1 , R_2 and R are selected from naturally occurring amino acid side chain moieties, n is constant, and Y is H, Ac or $-SO_2R$ as defined above, a library having on the order of 24,000 members [(20)(20)(20)(3)] is generated.


After screening the library against a protease, the library may then be recovered and screened with a second protease, and so on.

In addition, a library of inhibitors can be constructed and screened in a standard chromogenic assay. For example, the library may be constructed as follows, where the following example is merely representative of the inhibitor libraries that may be prepared in an analogous manner to the specific example provided below.




5 (See Wasserman et al., J. Org. Chem. 59:4364-6, 1994.)

A further alternative strategy is to link the library through the sidechain R group as shown below.




A library of aspartic protease inhibitors may be constructed having the following exemplary structure, and then cleaved from the resin and screened:



5

Similarly, for metalloproteases, a library having the exemplary structure shown below may be constructed and then cleaved from the resin to provide a library of hydroxamic acids:



The activity of the β -sheet mimetics of this invention may be further illustrated by reference to Table 15 2 which lists biologically active peptides. In particular, the peptides of Table 2 are known to have biological activity as substrates or inhibitors.

Table 2
Biologically Active Protease Inhibitors

(a) (D) FPR (Thrombin)

5 Enzyme 40:144-48, 1988


(b) (D) IEGR (Factor X)

Handbook of Synthetic Substrates for the Coagulation and Fibrinolytic Systems, H.C. Hemker, pp. 1-175, 1983, Martinus Nijhoff Publishers, The Hague.

10


In view of the above biologically active peptides, β -sheet mimetics of this invention may be substituted for one or more amino acids thereof. For 15 example, the following β -sheet modified peptides may be synthesized:

(a')



20

(b')




25

More generally, the β -sheet mimetics of this invention can be synthesized to mimic any number of

biologically active peptides by appropriate choice of the R₁, R₂, R₃, Y and Z moieties (as well as the A, B and C moieties of structure (I) itself). This is further illustrated by Table 3 which discloses various 5 modifications which may be made to the β -sheet mimetics of structure (I) to yield biologically active compounds. In Table 3, R₂ and R₃ are independently chosen from among the atoms or groups shown under the "R₂/R₃" column.












10





Table 3
Modifications to Structure (I) to Yield
Biological Active Compounds





















15

(I)





R ₁	R ₂ /R ₃	Y	Z
I. PROTEASE INHIBITORS			
A. Serine			
1. Thrombin C ₆ -C ₁₀ aromatic hydrogen (e.g., phenyl, benzyl, naphthyl), C ₁ -C ₁₀ aliphatic or cycloaliphatic, substituted C ₆ -C ₁₀ aromatic, -SiR ₃ , -CO ₂ H, -CO ₂ R			hydrogen, alkyl, aryl,
			
	(1)		
			
			
			
			
			R=aliphatic
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
			
		<img alt="Chemical structure of a secondary	

R ₁	R ₂ /R ₃	Y	Z
		$\textcircled{2} = \text{CH}_2\text{Cl}$ CF_3  cycloaliphatic	
		 m=1-2	
		 X=O, S, NH $\text{R=CO}_2\text{H, CO}_2\text{R, SO}_2\text{R, CSCF}_3$	
		 X=O, S, NH $\text{R=CO}_2\text{H, SO}_2\text{R, CO}_2\text{R}$	
		 $\text{R=CO}_2\text{H, CO}_2\text{R, SO}_2\text{R, COCR}_3$	
2. Elastase.	$\text{C}_1\text{-C}_{10}$ aliphatic	hydrogen or $\text{C}_1\text{-C}_{10}$ heterocyclic	acyl
		 $\textcircled{1}$	
		$\textcircled{2} = -\text{CH}_2-$ $-\text{CH}(\text{CH}_3)-$ or	
		 aromatic or aliphatic	

	R ₁	R ₂ /R ₃	Y	Z
3. Factor X	C ₁ -C ₁₀ aliphatic carboxylic	hydrogen		D(Ile) Acyl Dansyl
	aromatic carboxylate		① = 	
	C ₁ -C ₁₀ acidic heterocyclic			
				
				
				
		X = CH ₂ , NH		
				
				
		② = -CH ₂ Cl -CF ₃		
				
				
				
				
				
		③ = aliphatic cycloaliphatic peptide		

	R ₁	R ₂ /R ₃	Y	Z
B. Aspartic				
1. HIV1	C ₁ -C ₁₀ aliphatic or arginine	C ₁ -C ₁₀ aliphatic or		acyl
				
<p>① = C₁-C₁₀ aliphatic arginine</p> <p>or</p> 				
<p>① = C₁-C₁₀ aliphatic C₁-C₁₀ aromatic</p> <p>② = amino acid C₁-C₁₀ alkyl C₁-C₁₀ aryl acyl hydrogen</p>				
C. Cysteine				
1. Cathepsin B	C ₆ -C ₁₀ aromatic, C ₁ -C ₁₀ basic C ₁ -C ₁₀ aliphatic aromatic hydrophobic			benzyl acyl
				
<p>① = -CH₂C(=O)Ar -CH₂OAc -CH₂N₃ -H</p> 				
<p>② = C₁-C₁₀ aliphatic</p>				

	R ₁	R ₂ /R ₃	Y	Z
2. Calpain	C ₆ -C ₁₀ aromatic, C ₁ -C ₁₀ aliphatic, hydrophobic	C ₁ -C ₆ aliphatic		benzylic acyl
			(1) = C ₁ -C ₁₀ aromatic, hydrophobic	
			(2) = -CH ₂ F -CH ₂ N ₂ -CH ₂ OAc -H	
3. ACE	C ₁ -C ₁₀ aliphatic	hydrogen		dihydro- cinnamic, aromatic, aliphatic, acetyl
			(1) = -H -CH ₂ F -CH ₂ N ₂ -CH ₂ OAc	
			(2) = C ₁ -C ₁₀ aliphatic C ₁ -C ₁₀ aromatic	
<hr/>				
D. Metallo	R ₁	R ₂ /R ₃	Y	Z
1. ACE	C ₁ -C ₁₀ aliphatic	indoyl C ₁ -C ₆ aromatic	-OH	
				(1) = C ₁ -C ₁₀ aliphatic C ₁ -C ₁₀ aromatic

	R_1	R_2/R_3	Y	Z
2. Collagenase	C_1-C_{10} alkyl aromatic, C_1-C_{10} aliphatic, C_1-C_{10} basic	C_1-C_{10} aromatic, C_1-C_{10} aliphatic, C_1-C_{10} basic	$\begin{array}{c} \text{N} \\ \text{H} \\ \text{②} \end{array}$ ① = alkyl	hydroxyl  ① = hydrogen C_1-C_{10} alkyl
		or		
	C_6-C_{10} aromatic	C_1-C_{10} alkyl C_1-C_{10} aliphatic	$-NHOH$	hydroxyl  ① = hydrogen C_1-C_{10} alkyl, or
				

When the β -sheet mimetics of this invention are substituted for one or more amino acids of a biologically active peptide, the structure of the resulting β -sheet modified peptide (prior to cleavage from the solid support, such as PAM) may be represented by the following diagram, where AA₁ through AA₃ represent the same or different amino acids:



10


The precise β -sheet mimetic may be chosen by any of a variety of techniques, including computer modeling, randomization techniques and/or by utilizing natural

substrate selection assays. The β -sheet mimetic may also be generated by synthesizing a library of β -sheet mimetics, and screening such library members to identify active members as disclosed above.

5 Once the optimized β -sheet mimetic is chosen, modification may then be made to the various amino acids attached thereto. A series of β -sheet modified peptides having a variety of amino acid substitutions are then cleaved from the solid support and assayed to identify a
10 preferred substrate. It should be understood that the generation of such substrates may involve the synthesis and screening of a number of β -sheet modified peptides, wherein each β -sheet modified peptide has a variety of amino acid substitutions in combination with a variety of
15 different β -sheet mimetics. In addition, it should also be recognized that, following cleavage of the β -sheet modified peptide from the solid support, the Z moiety is AA₃ and the Y moiety is AA₂ and AA₁ in the above diagram. (While this diagram is presented for illustration,
20 additional or fewer amino acids may be linked to the β -sheet mimetic - that is, AA₃ may be absent or additional amino acids may be joined thereto; and AA₂ and/or AA₁ may be omitted or additional amino acids may be joined thereto).


25 Once a preferred substrate is identified by the procedures disclosed above, the substrate may be readily converted to an inhibitor by known techniques. For example, the C-terminal amino acid (in this case AA₁) may be modified by addition of a number of moieties known to
30 impart inhibitor activity to a substrate, including (but not limited to) -CF₃ (a known reversible serine protease inhibitor), -CH₂Cl (a known irreversible serine protease inhibitor), -CH₂N₂⁺ and -CH₂S(CH₃)₂⁺ (known cysteinyl

protease inhibitors), -NHOM (a known metalloprotease inhibitor),





5

(a known cysteinyl protease inhibitor), and



$R' = CH_2CH(CH_3)CH_2CH_3$ $R = CH_2CH(CH_3)_2$



10 (a known aspartyl protease inhibitor).

While the utility of the β -sheet mimetics of this invention have been disclosed with regard to certain embodiments, it will be understood that a wide variety and type of compounds can be made which includes the β -sheet mimetics of the present invention. For example, a β -sheet mimetic of this invention may be substituted for two or more amino acids of a peptide or protein. In addition to improving and/or modifying the β -sheet structure of a peptide or protein, especially with regard to conformational stability, the β -sheet mimetics of this invention also serve to inhibit proteolytic breakdown. This results in the added advantage of peptides or proteins which are less prone to proteolytic breakdown due to incorporation of the β -sheet mimetics of this invention.

In another aspect, the present invention encompasses pharmaceutical compositions prepared for storage or administration which comprise a therapeutically effective amount of a β -sheet mimetic or compound of the present invention in a pharmaceutically acceptable carrier. Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy.

The "therapeutically effective amount" of a compound of the present invention will depend on the route of administration, the type of warm-blooded animal being treated, and the physical characteristics of the specific animal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which as noted those skilled in the medical arts will recognize.

The "therapeutically effective amount" of the compound of the present invention can range broadly depending upon the desired affects and the therapeutic indication. Typically, dosages will be between about 0.01 mg/kg and 100 mg/kg body weight, preferably between about 0.01 and 10 mg/kg, body weight.

"Pharmaceutically acceptable carriers" for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remingtons *Pharmaceutical Sciences*, Mack Publishing Co. (A.R. Gennaro edit. 1985). For example, sterile saline and

phosphate-buffered saline at physiological pH may be used. Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. For example, sodium benzoate, sorbic acid and esters of 5 p-hydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspending agents may be used.

Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood 10 coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, the thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and 15 in which it is desired that blood coagulation be inhibited (e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stems, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems).

20 The thrombin inhibitors can be co-administered with suitable, anti-coagulation agents or thrombolytic agents such as plasminogen activators or streptokinase to achieve synergistic effects in the treatment of various 25 asacular pathologies. For example, thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter. They may also be 30 combined with heparin, aspirin, or warfarin.

The thrombin inhibitors of the invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers,

tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an anti-aggregation agent or treating ocular build up of fibrin. The compounds may be administered intraocularly or topically as well as orally or parenterally.

The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The thrombin inhibitors may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartarnide-phenol, or

polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, 5 polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydibydropryans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

10 The dose and method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. When administration is to be parenteral, such 15 as intravenous on a daily basis, injectable pharmaceutical compositions can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

20 Tablets suitable for oral administration of active compounds of the invention (e.g., structures (47), (20b), (37), (39), (29a), (35), (45), (51), (29b), (41) and (13b)), can be prepared as follows:

	<u>Amount-mg</u>		
Active Compound	25.0	50.0	100.0
Microcrystalline cellulose	37.25	100.0	200.0
Modified food corn starch	37.25	4.25	8.5
Magnesium stearate	0.50	0.75	1.5

25

All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved,

dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

5 An intravenous dosage form of the above-indicated active compounds may be prepared as follows:

Active Compound	0.5-10.0mg
Sodium Citrate	5-50mg
Citric Acid	1-15mg
Sodium Chloride	1-8mg
Water for Injection (USP)	q.s. to 1 ml

Utilizing the above quantities, the active 10 compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopoeia/National Formulary for 1995, published by United States Pharmacopoeia Convention, 15 Inc., Rockville, Maryland, copyright 1994).

Compounds of the present invention when made and selected as disclosed are useful as potent inhibitors of thrombin *in vitro* and *in vivo*. As such, these compounds are useful as *in vitro* diagnostic reagents to prevent the 20 clotting of blood and as *in vivo* pharmaceutical agents to prevent thrombosis in mammals suspected of having a condition characterized by abnormal thrombosis.

The compounds of the present invention are useful as *in vitro* diagnostic reagents for inhibiting 25 clotting in blood drawing tubes. The use of stoppered test tubes having a vacuum therein as a means to draw blood obtained by venipuncture into the tube is well known in the medical arts (Kasten, B.L., "Specimen Collection,"

Laboratory Test Handbook, 2nd Edition, Lexi-Comp Inc., Cleveland pp. 16-17, Edits. Jacobs, D.S. et al. 1990). Such vacuum tubes may be free of clot-inhibiting additives, in which case, they are useful for the 5 isolation of mammalian serum from the blood they may alternatively contain clot-inhibiting additives (such as heparin salts, EDTA salts, citrate salts or oxalate salts), in which case, they are useful for the isolation of mammalian plasma from the blood. The compounds of the 10 present invention are potent inhibitors of factor Xa or thrombin, and as such, can be incorporated into blood collection tubes to prevent clotting of the mammalian blood drawn into them.

The compounds of the present invention are used 15 alone, in combination of other compounds of the present invention, or in combination with other known inhibitors of clotting, in the blood collection tubes. The amount to be added to such tubes is that amount sufficient to inhibit the formation of a clot when mammalian blood is 20 drawn into the tube. The addition of the compounds to such tubes may be accomplished by methods well known in the art, such as by introduction of a liquid composition thereof, as a solid composition thereof, or liquid composition which is lyophilized to a solid. The 25 compounds of the present invention are added to blood collection tubes in such amounts that, when combined with 2 to 10 mL of mammalian blood, the concentration of such compounds will be sufficient to inhibit clot formation. Typically, the required concentration will be about 1 to 30 10,000 nM, with 10 to 1000 nM being preferred.

The following examples are offered by way of illustration, not limitation.

EXAMPLES


Example 1Synthesis of Representative β -Sheet Mimetic

5 This example illustrates the synthesis of a representative β -sheet mimetic of this invention.

Synthesis of Structure (1):

10

Phenylalanine benzaldimine, structure (1), was synthesized as follows. To a mixture of L-phenylalanine methyl ester hydrochloride (7.19 g, 33.3 mmol) and benzaldehyde (3.4 ml, 33.5 mmol) stirred in CH_2Cl_2 (150 ml) at room temperature was added triethylamine (7.0 ml, 50 mmol). Anhydrous magnesium sulfate (2 g) was added to the resulting solution and the mixture was stirred for 14 h then filtered through a 1 inch pad of Celite with CH_2Cl_2 . The filtrate was concentrated under reduced pressure to ca. one half of its initial volume then diluted with an equal volume of hexanes. The mixture was extracted twice with saturated aqueous NaHCO_3 , H_2O and brine then dried over anhydrous Na_2SO_4 and filtered. Concentration of the filtrate under vacuum yielded 8.32 g (93% yield) of colorless oil. ^1H NMR analysis indicated nearly pure (>95%) phenylalanine benzaldimine. The crude product was used without further purification.

Synthesis of Structure (2):


(2)

α -Allylphenylalanine benzaldimine, structure 5 (2), was synthesized as follows. To a solution of diisopropylamine (4.3 ml, 33 mmol) stirred in THF (150 ml) at -78°C was added dropwise a solution of *n*-butyllithium (13 ml of a 2.5 M hexane solution, 33 mmol). The resulting solution was stirred for 20 min. then a solution 10 of phenylalanine benzaldimine (7.97 g, 29.8 mmol) in THF (30 ml) was slowly added. The resulting dark red-orange solution was stirred for 15 min. then allyl bromide (3.1 ml, 36 mmol) was added. The pale yellow solution was stirred for 30 min. at -78°C then allowed to warm to room 15 temperature and stirred an additional 1 h. Saturated aqueous ammonium chloride was added and the mixture was poured into ethyl acetate. The organic phase was separated and washed with water and brine then dried over anhydrous sodium sulfate and filtered. Concentration of 20 the filtrate under vacuum yielded 8.54 g of a viscous yellow oil. Purification by column chromatography yielded 7.93 g (87%) of α -allylphenylalanine benzaldimine as a viscous colorless oil.

Synthesis of Structure (3):

α -Allylphenylalanine hydrochloride, structure 5 (3), was synthesized as follows. To a solution of α -allylphenylalanine benzaldimine (5.94 g, 19.3 mmol) stirred in methanol (50 ml) was added 5% aqueous hydrochloric acid (10 ml). The solution was stirred at room temperature for 2 h then concentrated under vacuum to 10 an orange-brown caramel. The crude product was dissolved in CHCl_3 (10 ml) and the solution was heated to boiling. Hexanes (~150 ml) were added and the slightly cloudy mixture was allowed to cool. The liquid was decanted away from the crystallized solid then the solid was rinsed with 15 hexanes and collected. Removal of residual solvents under vacuum yielded 3.56 g (72%) of pure α -allylphenylalanine hydrochloride as a white crystalline solid.

^1H NMR (500 MHz, CDCl_3) δ 8.86 (3 H, br s), 7.32-20 7.26 (5H, m), 6.06 (1 H, dddd, J = 17.5, 10.5, 7.6, 7.3 Hz), 5.33 (1H, d, J = 17.5 Hz), 5.30 (1 H, d, J = 10.5 Hz), 3.70 (3 H, s), 3.41 (1 H, d, J = 14.1 Hz), 3.35 (1 H, d, J = 14.1 Hz), 2.98 (1 H, dd, J = 14.5, 7.3 Hz), 2.88 (1 H, dd, J = 14.5, 7.6 Hz).

Synthesis of Structure (4):

(4)

N-tert-butyloxycarbonyl- α -allylphenylalanine,

5 structure (4) was synthesized as follows. To a solution of D,L α -allylphenylalanine hydrochloride (565 mg, 2.21 mmol) stirred in a mixture of THF (15 ml) and water (5 ml) was added di-tert-butyl dicarbonate followed by careful addition of solid sodium bicarbonate in small portions. 10 The resulting two phase mixture was vigorously stirred at room temperature for 2 days then diluted with ethyl acetate. The organic phase was separated and washed with water and brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum 15 yielded a colorless oil that was purified by column chromatography (5 to 10% EtOAc in hexanes gradient elution) to yield 596 mg (86%) of N-tert-butyloxycarbonyl- α -allylphenylalanine.

TLC R_f = 0.70 (silica, 20% EtOAc in hexanes); 20 1 H NMR (500 MHz, CDCl₃) δ 7.26-7.21 (3 H, m), 7.05 (2 H, d, J = 6.1 Hz), 5.64 (1 H, dddd, J = 14.8, 7.6, 7.2, 7.2 Hz), 5.33 (1 H, br s), 5.12-5.08 (2 H, m), 3.75 (3 H, s), 3.61 (1 H, d, J = 13.5 Hz), 3.21 (1 H, dd, J = 13.7, 7.2 Hz), 3.11 (1 H, d, J = 13.5 Hz), 2.59 (1 H, dd, J = 13.7, 7.6 Hz), 1.47 (9 H, s).

Synthesis of Structure (5):

An aldehyde of structure (5) was synthesized as follows. Ozone was bubbled through a solution of 2.10 g (6.57 mmol) of the structure (4) olefin stirred at -78°C in a mixture of CH_2Cl_2 (50 ml) and methanol (15 ml) until the solution was distinctly blue in color. The solution was stirred an additional 15 min. then dimethyl sulfide was slowly added. The resulting colorless solution was stirred at -78°C for 10 min. then allowed to warm to room temperature and stirred for 6 h. The solution was concentrated under vacuum to 2.72 g of viscous pale yellow oil which was purified by column chromatography (10 to 20% EtOAc in hexanes gradient elution) to yield 1.63 g of pure aldehyde as a viscous colorless oil.

TLC R_f = 0.3 (silica, 20% EtOAc in hexanes); ^1H NMR (500 MHz, CDCl_3) δ 9.69 (1 H, br s), 7.30-7.25 (3 H, m,), 7.02 (2 H, m,), 5.56 (1 H, br s), 3.87 (1 H, d, J = 17.7 Hz,), 3.75 (3 H, s,), 3.63 (1 H, d, J = 13.2 Hz), 3.08 (1 H, d, J = 17.7 Hz), 2.98 (1 H, d, J = 13.2 Hz,), 1.46 (9 H, s,).

Synthesis of Structure (6):

A hydrazone of structure (6) was synthesized as follows. To a solution of the aldehyde of structure (5) (1.62 g, 5.03 mmol) stirred in THF (50 ml) at room temperature was added hydrazine hydrate (0.32 ml, 6.5 mmol). The resulting solution was stirred at room temperature for 10 min. then heated to reflux for 3 days. The solution was allowed to cool to room temperature then concentrated under vacuum to 1.59 g (105% crude yield) of colorless foam. The crude hydrazone product, structure 10 (6), was used without purification.

TLC R_f = 0.7 (50% EtOAc in hexanes); ^1H NMR (500 MHz, CDCl_3) δ 8.55 (1 H, br s), 7.32-7.26 (3 H, m), 7.17 (1 H, br s), 7.09 (2 H, m), 5.55 (1 H, br s), 3.45 (1 H, d, J = 17.7 Hz), 3.29 (1 H, d, J = 13.5 Hz), 2.90 (1 H, d, J = 13.5 Hz), 2.88 (1 H, dd, J = 17.7, 1.3 Hz), 1.46 (9 H, s); MS (CI+, NH_3) m/z 304.1 ($M + \text{H}^+$).

Synthesis of Structure (7):



20


A cyclic hydrazide of structure (7) was synthesized as follows. The crude hydrazone of structure (6) (55 mg, 0.18 mmol) and platinum oxide (5 mg, 0.02 mmol) were taken up in methanol and the flask was fitted 25 with a three-way stopcock attached to a rubber balloon. The flask was flushed with hydrogen gas three times, the balloon was inflated with hydrogen, and the mixture was stirred vigorously under a hydrogen atmosphere for 17 hours. The mixture was filtered through Celite with ethyl 30 acetate and the filtrate was concentrated under vacuum to a white form. Purification of the white foam by flash

chromatography yielded 44 mg of the pure cyclic hydrazide of structure (7) (80%).

¹H NMR (500 MHz, CDCl₃) δ 7.34-7.28 (3 H, m), 7.21 (2 H, m), 6.95 (1 H, br s), 5.29 (1 H, br s), 3.91 (1 H, br s), 3.35 (1 H, d, J = 12.9 Hz), 3.00 (1 H, ddd, J = 13.9, 5.3, 5.0 Hz), 2.96 (1 H, d, J = 12.9 Hz), 2.67 (1 H, br m), 2.38 (1 H, br m), 2.30 (1 H, ddd, J = 13.9, 5.4, 5.0 Hz), 1.45 (9 H, s); MS (CI+, NH₃) m/z 306.2 (M + H⁺).

10


Synthesis of Structure (8):



Structure (8) was synthesized as follows. To a solution of the cyclic hydrazide of structure (7) (4.07 g, 13.32 mmol) stirred in ethyl acrylate (200 ml) at 90°C was added formaldehyde (1.2 mL of a 37% aqueous solution). The mixture was heated to reflux for 15 h then allowed to cool to room temperature and concentrated under vacuum to a white foam. The products were separated by column chromatography (5% then 10% acetone/chloroform) to yield 0.651 g of the least polar diastereomer of the bicyclic ester, structure (8b), and a more polar diastereomer (8a). The impure fractions were subjected to a second chromatography to afford more pure structure (8b), 25% combined yield.


¹H NMR (500 MHz, CDCl₃) δ 7.27-7.21 (3 H, m), 7.09 (2 H, d, J = 6.5 Hz), 5.59 (1 H, br s), 4.52 (1 H, dd, J = 9.1, 3.4 Hz), 4.21 (2 H, m), 3.40 (1 H, d, J = 12.5 Hz), 3.32 (1 H, d, J = 12.5 Hz), 3.10 (2 H, m), 2.79 (1 H, br m), 2.66 (1 H, br m), 2.79 (1 H, br m), 2.66 (1 H, br m), 2.54 (1 H, br m), 2.46 (1 H, m), 2.18 (1 H, m),

1.44 (9 H, s), 1.28 (3 H, t, $J = 7.0$ Hz); MS (CI+, NH₃)
418.4 (M + H⁺).




5

(8b)



(8a)


Synthesis of Structure (9b):



(9b)


10

Structure (9b) was synthesized as follows. To a solution of the least polar ethyl ester (i.e., structure (8b)) (31 mg, 0.074 mmol) stirred in THF (1 ml) was added 15 aqueous lithium hydroxide (1 M, 0.15 ml). The resulting mixture was stirred at room temperature for 2 h then the reaction was quenched with 5% aqueous citric acid. The mixture was extracted with ethyl acetate (2 x) then the combined extracts were washed with water and brine. The 20 organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to a colorless glass. The crude acid, structure (9b), was used in subsequent experiments without further purification.


Synthesis of Structure (10b):

(10b)

5 Structure (10b) was synthesized as follows. The crude acid of structure (9b) (30 mg, 0.074 mmol), HArg(PMC)pNA (41 mg, 0.074 mmol), and HOBt (15 mg, 0.098 mmol) were dissolved in THF (1 ml) then diisopropylethylamine (0.026 ml, 0.15 mmol) was added
10 followed by EDC (16 mg, 0.084 mmol). The resulting mixture was stirred at room temperature for 4 h then diluted with ethyl acetate and extracted with 5% aqueous citric acid, saturated aqueous sodium bicarbonate, water and brine. The organic layer was dried over anhydrous
15 sodium sulfate, filtered and concentrated under vacuum to 54 mg of pale yellow glass. The products were separated by column chromatography to yield 33 mg (50%) of a mixture of diastereomers of the coupled (i.e., protected) product, structure (10b). MS (Cl+, NH3) m/z 566.6 (M + H+).

Synthesis of Structure (11b):

5 A β -sheet mimetic of structure (11b) was synthesized as follows. A solution of 0.25 ml of H₂O, 0.125 ml of 1,2-ethanedithiol and 360 mg of phenol in 5 ml of TFA was prepared and the protected product of structure (10b) (33 mg, 0.035 mmol) was dissolved in 2 ml of this
10 solution. The resulting solution was stirred at room temperature for 3 h then concentrated under reduced pressure. Ether was added to the concentrate and the resulting precipitate was collected by centrifugation. The precipitate was triturated with ether and centrifuged
15 two more times then dried in a vacuum desiccator for 14 h. The crude product (14 mg) was purified by HPLC chromatography to yield the β -sheet mimetic of structure (11b). MS (Cl⁺, NH₃) m/z 954.8 (M + Na⁺).

Synthesis of Structure (12b):


(12b)

5 Structure (12b) was synthesized as follows. To a solution of the crude acid of structure (9b) (24 mg, 0.062 mmol) and N-methylmorpholine (0.008 ml), stirred in THF (1 ml) at -50°C was added isobutyl chloroformate. The resulting cloudy mixture was stirred for 10 min. then 10 0.016 ml (0.14 mmol) of N-methylmorpholine was added followed by a solution of HArg(Mtr)CH₂Cl (50 mg, 0.068 mmol) in THF (0.5 ml). The mixture was kept at -50°C for 20 min. then was allowed to warm to room temperature during 1 h. The mixture was diluted with ethyl acetate 15 and extracted with 5% aqueous citric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to yield 49 mg of colorless glass, structure (12). Separation by column 20 chromatography yielded 12 mg of a less polar diastereomer and 16 mg of a more polar diastereomer.

25 ¹H NMR (500 MHz, CDCl₃) δ 7.93 (1 H, br s), 7.39-7.31 (3 H, m), 7.16 (2 H, d, J = 6.9 Hz), 6.52 (1 H, s), 6.30 (1 H, br s), 5.27 (1 H, s), 4.74 (1 H, dd, J = 9.1, 6.9 Hz), 4.42 (1 H, br d, J = 6.8 Hz), 4.33 (1 H, d, J =

6.8 Hz), 3.82 (3 H, s), 3.28 (1 H, d, J = 13.3 Hz), 3.26-3.12 (4 H, m), 2.98 (1 H, d, J = 13.3 Hz), 2.69 (3 H, s), 2.60 (3 H, s), 2.59-2.33 (4 H, m), 2.25-2.10 (3 H, m), 2.11 (3 H, s), 1.77 (1 H, br m), 1.70-1.55 (3 H, br m), 5 1.32 (9 H, s).

Synthesis of Structure (13b):




10

A β -sheet mimetic of structure (13b) was synthesized as follows. The more polar diastereomer of structure (12b) (16 mg, 0.021 mmol) was dissolved in 95% TFA/H₂O (1 ml) and the resulting solution was stirred at 15 room temperature for 6 h then concentrated under vacuum to 11 mg of crude material. The crude product was triturated with ether and the precipitate was washed twice with ether then dried under high vacuum for 14 h. ¹H NMR analysis indicated a 1:1 mixture of fully deprotected product and 20 product containing the Mtr protecting group. The mixture was dissolved in 95% TFA/H₂O and stirred for 2 days and the product was recovered as above. Purification of the product by HPLC yielded 5 mg of the pure compound of structure (13b). MS (EI⁺) m/z 477.9 (M⁺).

25

Example 2Synthesis of Representative β -Sheet Mimetic

This example illustrates the synthesis of a
5 further representative β -sheet mimetic of this invention.

Synthesis of Structure (14):

(14)

10

N,O-Dimethyl hydroxamate, structure (14), was synthesized as follows. To a mixture of Boc-N⁹-4-methoxy-2,3,6-trimethylbenzenesulfonyl-L-arginine (8.26 g, 14.38 mmol), N,O-dimethylhydroxylamine hydrochloride (2.79 g, 28.5 mmol) and 1-hydroxybenzotriazole hydrate (2.45 g, 16.0 mmol) stirred in THF (150 ml) at ambient temperature was added N,N-diisopropylethylamine (7.5 ml, 43 mmol) followed by solid EDC (3.01 g, 15.7 mmol). The resulting solution was stirred for 16h then diluted with 20 ethyl acetate (200 ml) and extracted sequentially with 5% aqueous citric acid, saturated aqueous sodium bicarbonate, water and brine. The organic solution was dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded 7.412 g of white foam.


25

¹H NMR (500Mhz, CDCl₃): δ 6.52 (1 H, s), 6.17 (1 H, br s), 5.49 (1 H, d, J=8.8Hz), 4.64 (1 H, br t), 3.82 (3H, s), 3.72 (3H, s), 3.36 (1 H, br m), 3.18 (3H, s), 3.17 (1 H, br m), 2.69 (3H, s), 2.61 (3H, s), 2.12 (3H,

2), 1.85-1.55 (5 H, m), 1.41 (9 H, s); MS (FB+): m/z 530.5 (M+H⁺).

Synthesis of Structure (15):


5



(15)

Structure (15) was synthesized as follows. To a solution of the arginine amide (7.412 g, 13.99 mmol) 10 stirred in dichloromethane (150 ml) at room temperature was added N,N-diisopropylethylamine (2.9 ml, 17 mmol) followed by di-tert-butyldicarbonate (3.5 ml, 15.4 mmol) and N,N-dimethylaminopyridine (0.175 g, 1.43 mmol). The resulting solution was stirred for 1.5h then poured into 15 water. The aqueous layer was separated and extracted with two 100ml portions of dichloromethane. The combine extracts were shaken with brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded a white foam that was 20 purified by flash chromatography to yield 8.372 g of white foam.

¹H NMR (500MHz, CDCl₃): δ 9.79 (1 H, s), 8.30 (1 H, t, J=4.96), 6.54 (1 H, s), 5.18 (1 H, d, J=9.16 Hz), 4.64 (1 H, m), 3.83 (3 H, s), 3.74 (3 H, s), 3.28 (2 H, dd, J=12.6, 6.9 Hz), 3.18 (3 H, s), 2.70 (3 H, s), 2.62 (3 H, s), 2.14 (3 H, s), 1.73-1.50 (5 H, m), 1.48 (9H, s), 1.42 (9 H, s); MS (FB+): m/z 630.6 (M+H⁺).

Synthesis of Structure (16):

(16)

5


The arginal, structure (16), was synthesized as follows. To a solution of the arginine amide structure (15) stirred in toluene at -78°C under a dry argon atmosphere was added a solution of diisobutylaluminum hydride in toluene (1.0 M, 7.3ml) dropwise over a period of 15 minutes. The resulting solution was stirred for 30 minutes then a second portion of diisobutylaluminum hydride (3.5ml) was added and stirring was continued for 15 minutes. Methanol (3ml) was added dropwise and the solution was stirred at -78°C for 10 minutes then allowed to warm to room temperature. The mixture was diluted with ethyl acetate (100ml) and stirred vigorously with 50 ml of saturated aqueous potassium sodium tartrate for 2.5h. The aqueous phase was separated and extracted with ethyl acetate (2 x 100ml). The extracts were combined with the original organic solution and shaken with brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded a white foam that was separated by flash chromatography to yield 1.617g of the aldehyde as a white foam.

¹H NMR (500MHz, CDCl₃): δ 9.82 (1 H, s), 9.47 (1 H, s), 8.35 (1 H, br t), 6.55 (1 H, s), 5.07 (1 H, d, J=6.9 Hz), 4.18 (1 H, br m), 3.84 (3 H, s), 3.25 (2 H, m),

2.70 (3 H, s), 2.62 (3 H, s), 2.14 (3 H, s), 1.89 (1 H, m), 1.63- 1.55 (4 H, m), 1.49 (9H, s), 1.44 (9 H, s); MS (FB+): m/z 571.6 (M+H⁺).

5

Synthesis of Structure (17):



(17)


Hydroxybenzothiazole, structure (17), was synthesized as follows. To a solution of benzothiazole (1.55 ml, 14 mmol) stirred in anhydrous diethyl ether (60 ml) at -78°C under a dry argon atmosphere was added a solution of *n*-butyllithium (2.5 M in hexane, 5.6 ml, 14 mmol) dropwise over a period of 10 minutes. The resulting orange solution was stirred for 45 minutes then a solution of the arginal structure (16) (1.609 g, 2.819 mmol) in diethyl ether (5ml) was slowly added. The solution was stirred for 1.5 h then saturated aqueous ammonium chloride solution was added and the mixture was allowed to warm to room temperature. The mixture was extracted with ethyl acetate (3 x 100 ml) and the combined extracts were extracted with water and brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded a yellow oil that was purified by flash chromatography (30% then 40% ethyl acetate/hexanes eluent) to yield 1.22 g of the hydroxybenzothiazoles (ca. 2:1 mixture of diastereomers) as a white foam.

The mixture of hydroxybenzothiazoles (1.003 g, 1.414 mmol) was stirred in CH_2Cl_2 (12 ml) at room temperature and trifluoroacetic acid (3 ml) was added. The resulting solution was stirred for 1.5h then 5 concentrated under reduced pressure to yield 1.22 g of the benzothiazolylarginol trifluoroacetic acid salt as a yellow foam.

MS (EI $^+$): m/z 506.2 ($M + H^+$).

10

Synthesis of Structure (18b):




(18b)

The bicyclic compound, structure (18b) was 15 synthesized as follows. The bicyclic acid of structure (9b) from Example 1 (151 mg, 0.387 mmol) and HOBt hydrate (71 mg, 0.46 mmol) were dissolved in THF (5 ml) and diisopropylethylamine (0.34 ml, 1.9 mmol) was added followed by EDC (89 mg, 0.46 mmol). After stirring for 20 ten minutes a solution of the benzothiazolylarginol trifluoroacetic acid salt (structure (17) 273 mg, 0.372 mmol) in THF (1 ml) was added along with a THF (0.5 ml) rinse. The mixture was stirred at room temperature for 15 h then diluted with ethyl acetate and extracted 25 sequentially with 5% aqueous citric acid, saturated aqueous sodium bicarbonate, water and brine. The organic

solution was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to 297 mg of a yellow glass. ¹H NMR analysis indicated a mixture of four diastereomeric amides which included structure (18b).

5 MS (ES+): m/z 877 (M⁺).


Synthesis of Structure (19b):



(19b)

10

Structure (19b) was synthesized as follows. The crude hydroxybenzothiazole (247 mg, 0.282 mmol) was dissolved in CH₂Cl₂ (5 ml) and Dess-Martin periodinane (241 mg, 0.588 mmol) was added. The mixture was stirred at room temperature for 6h then diluted with ethyl acetate and stirred vigorously with 10% aqueous sodium thiosulfate for 10 minutes. The organic solution was separated and extracted with saturated aqueous sodium bicarbonate, water and brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded 252 mg of yellow glass. ¹H NMR analysis indicated a mixture of two diastereomeric ketobenzothiazoles which included structure (19b).

Synthesis of Structure (20b):

(20b)

5 The ketobenzothiazole, structure (20), was synthesized as follows. Ketobenzothiazole (19) (41 mg, 0.047 mmol) was dissolved in 95% aqueous trifluoroacetic (0.95 ml) acid and thioanisole (0.05 ml) was added. The resulting dark solution was stirred for 30 hours at room 10 temperature then concentrated under vacuum to a dark brown gum. The gum was triturated with diethyl ether and centrifuged. The solution was removed and the solid remaining was triturated and collected as above two more times. The yellow solid was dried in a vacuum desiccator 15 for 2 hours then purified by HPLC (Vydac reverse phase C-4 column (22 x 250 mm ID). Mobile phase: A = 0.05% TFA in water; B = 0.05% TFA in acetonitrile. The flow rate was 10.0 mL/min. The gradient used was 8% B to 22% B over 25 min, and isocratic at 22% thereafter. The peak of 20 interest (structure (20b)) eluted at 42 minutes) to give 2.5 mg of the deprotected product, structure (20b).

MS (ES+): 563.5 (M + H⁺).

Example 3Activity of a Representative β -Sheet Mimetic
as a Proteolytic Substrate

5 This example illustrates the ability of a representative β -sheet mimetic of this invention to selectively serve as a substrate for thrombin and Factor VII. The β -sheet mimetic of structure (11b) above was synthesized according the procedures disclosed in Example
10 1, and used in this experiment without further modification.

Both the thrombin and Factor VII assays of this experiment were carried out at 37°C using a Hitachi UV/Vis spectrophotometer (model U-3000). Structure (11b) was
15 dissolved in deionized water. The concentration was determined from the absorbance at 342 nm. Extinction coefficient of 8270 liters/mol/cm was employed. The rate of structure (11b) hydrolysis was determined from the change in absorbance at 405 nm using an extinction
20 coefficient for p-nitroaniline of 9920 liters/mol/cm for reaction buffers. Initial velocities were calculated from the initial linear portion of the reaction progress curve. Kinetic parameters were determined by unweighted nonlinear least-squares fitting of the simple Michaelis-Menten
25 equation to the experimental data using GraFit (Version 3.0, Eritacus Software Limited).

For the thrombin assay, experiments were performed in pH 8.4 Tris buffer (Tris, 0.05M; NaCl, 0.15M). 6.4 NIH units of bovine thrombin (from Sigma)
30 were dissolved into 10 ml of the assay buffer to yield 10 nM thrombin solution. In a UV cuvette, 130 to 148 μ l of the buffer and 100 μ l of the thrombin solutions were added, preincubated at 37°C for 2 minutes, and finally 2 to 20 microliters (to make the final volume at 250 μ l) of

0.24 mM structure (11b) solution was added to initiate the reaction. The first two minutes of the reactions were recorded for initial velocity determination. Eight structure (11b) concentration points were collected to obtain the kinetic parameters. k_{cat} and K_M were calculated to be 50 s^{-1} and $3 \mu\text{M}$, respectively. k_{cat}/K_M was found to be $1.67 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$.

For the Factor VII assay, pH 8.0 Tris buffer (0.05 M Tris, 5 mM CaCl_2 , 0.15 M NaCl , 0.1% Tween 20, 0.1% BSA) was used. 10 μl of 20 μM human Factor VIIa (FVIIa) and 22 μM of human tissue factor (TF) was brought to assay buffer to make 160 nM FVIIa and TF solutions, respectively. 40 to 48 μl of buffer, 25 μl of FVIIa and 25 μl TF solution were added to a cuvette, and incubated at 37°C for 5 minutes, then 2 to 10 μl of 2.4 mM structure (11b) solution was added to the cuvette to initiate reaction (final volume was 100 ml). The initial 3 minutes reaction progress curves were recorded. Five structure (11b) concentration points were collected. The initial rates were linear least-square fitted against the concentrations of structure (11b) with GraFit. The k_{cat}/K_M was calculated from the slope and found to be $17,500 \text{ M}^{-1} \text{ s}^{-1}$.

In both the thrombin and Factor VII assay of this experiment, (D)FPR-PNA was run as a control. Activity of structure (11b) compared to the control was 0.76 and 1.38 for thrombin and Factor VII, respectively (Factor VII: $K_{cat}/K_M = 1.27 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$; thrombin: $K_{cat}/K_M = 2.20 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$).

Example 4Activity of a Representative β -Sheet Mimetic
as a Protease Inhibitor

5 This example illustrates the ability of a representative β -sheet mimetic of this invention to function as a protease inhibitor for thrombin, Factor VII, Factor X, urokinase, tissue plasminogen activator (t-PA), protein C, plasmin and trypsin. The β -sheet mimetic of
10 structure (13b) above was synthesized according to the procedures disclosed in Example 1, and used in this experiment.

All inhibition assays of this experiment were performed at room temperature in 96 well microplates using
15 a Bio-Rad microplate reader (Model 3550). 0.29 mg of structure (13b) was dissolved into 200 ml of 0.02 N hydrochloric acid deionized water solution. This solution (2.05 mM) served as the stock solution for all the inhibition assays. The hydrolysis of chromogenic
20 substrates was monitored at 405 nm. The reaction progress curves were recorded by reading the plates typically 90 times with 30 seconds to 2 minute intervals. The initial rate were determined by unweighted nonlinear least-squares fitting to a first order reaction in GraFit. The
25 determined initial velocities were then nonlinear least-square fitted against the concentrations of structure (13b) using GraFit to obtain IC₅₀. Typically, eight structure (13b) concentration points were employed for IC₅₀ determination.

30 For the thrombin assay, N-p-tosyl-Gly-Pro-Arg-pNA (from Sigma) was used at 0.5 mM concentration in 1% DMSO (v/v) pH 8.4 Tris buffer as substrate. From structure (13b) stock solution two steps of dilution were made. First, 1:2000 dilution into 0.02 N hydrochloride

solution, then 1:100 dilution into pH 8.4 Tris buffer. The final dilution of structure (13b) served as the first point (10 nM). Seven sequential dilutions were made from the first point with a dilution factor of 2. Into each 5 reaction well, 100 μ l of 10 nM thrombin solution and 50 μ l of structure (13b) solution was added. The mixture of the enzyme and inhibitor was incubated for 20 minutes, then 100 μ l of 0.5 mM substrate solution was added to initiate the reaction. The IC₅₀ of structure (13b) against 10 thrombin was found to be 1.2 \pm 0.2 nM.

In the Factor VII assay, S-2288 (from Pharmacia), D-Ile-Pro-Arg-pNA was used at 20 μ M in deionized water as substrate. From the stock of structure (13b), a 1:100 dilution was made into pH 8.0 Tris buffer. 15 This dilution served as the first point of the inhibitor (20 μ M). From this concentration point 6 more sequential dilutions were made with a dilution factor of 2. 50 μ l of 16 nM FVIIa and TF complex solution and 40 μ l of the inhibitor solutions were added into each well, the 20 mixtures were incubated for 20 minutes before 10 μ l of 20 mM S-2288 was added. IC₅₀ of structure (13b) against factor VII was found to be 140 \pm 3 nM.

In the Factor X assay, buffer and substrate are the same as used for thrombin assay. A 1:100 dilution was 25 made into pH 8.4 Tris buffer to serve as the first point. Seven dilutions with a dilution factor of 2 were made. The assay protocol is the same as for thrombin except 25 nM of bovine factor Xa (from Sigma) in pH 8.4 Tris buffer was used instead of thrombin. IC₅₀ of structure (13b) 30 against factor X was found to be 385 \pm 17 nM.

In the urokinase assay, buffer was pH 8.8 0.05 M Tris and 0.05 M NaCl in deionized water. S-2444 (from Sigma), pyroGlu-Gly-Arg-pNA at 0.5 mM in water was utilized as substrate. The same dilution procedure was

used as for Factor VII and Factor X. Assay protocol is the same as for thrombin except 18.5 nM of human urokinase (from Sigma) was utilized. IC₅₀ was found to be 927±138 nM.

5 Tissue Plasminogen Activator (t-PA): Buffer, substrate and the dilution scheme of structure (13b) were the same as utilized for Factor VII assay.

10 Activated Protein C (aPC): Buffer was the same as used in thrombin assay. 1.25 mM S-2366 in the assay buffer was utilized as substrate. Dilutions of structure (13b) were the same as in urokinase assay.

15 Plasmin: Buffer (see thrombin assay); S-2551 (from Pharmacia), D-Val-Leu-Lys-pNA at 1.25 mM in assay buffer was utilized as substrate. For dilutions of structure (13b) (see urokinase assay).

20 In the trypsin assay, pH 7.8 Tris (0.10 M Tris and 0.02 M CaCl₂) was utilized as the buffer. BAPNA (from Sigma) was used at 1 mg/ml in 1% DMSO (v/v) deionized water solution as substrate. The same dilutions of structure (13b) were made as for Factor VII assay. 40 µl of 50 µg/ml bovine trypsin (from Sigma) and 20 µl of structure (13b) solution were added to a reaction well, the mixture was incubated for 5 minutes before 40 µl of 1 mg/ml BAPNA was added to initiate the reaction. The IC₅₀ 25 of structure (13b) against trypsin was found to be 160±8 nM.

 In the above assays, (D)FPR-CH₂Cl ("PPACK") was run as a control. Activity of structure (13b) compared to the control was enhanced (see Table 4).

Table 4

Enzymes	PPACK	IC ₅₀ (nM) Structure (13b)
Thrombin	1.5	1.2
Factor VII	200	140
Factor X	165	385
Protein C	281	528
Plasmin	699	978
Trypsin	212	16
Urokinase	508	927
t-PA	106	632

With respect to prothrombin time (PT), this was determined by incubating (30 minutes at 37°C) 100 µl of control plasma (from Sigma) with 1-5 µl of buffer (0.05 M Tris, 0.15 M NaCl, pH=8.4) or test compound (i.e., PPACK or structure (13b)) in buffer. Then 200 µl of prewarmed (at 37°C for ~10 minutes) thromboplastin with calcium (from Sigma) was rapidly added into the plasma sample. The time required to form clot was manually recorded with a stopwatch (see Table 5), and was found to be comparable with PPACK.

15

Table 5

Concentration	PT (second)	
	PPACK	Structure (13b)
0 (Control)	13	13
1 pM	--	13
10 pM	--	17
50 pM	--	18
100 pM	--	23
200 pM	--	24
500 pM	15	27
1 nM	18	30
10 nM	22	31
20 nM	25	--
30 nM	--	31
40 nM	28	--
50 nM	--	30
60 nM	30	--
80 nM	31	33

Example 5Activity of a Representative β -Sheet Mimetic
as a Protease Inhibitor

5

This example illustrates the ability of a further representative β -sheet mimetic of this invention to function as an inhibitor for thrombin, Factor VII, Factor X, urokinase, Tissue Plasminogen Activator, 10 Activated Protein C, plasmin, tryptase and trypsin. The β -sheet mimetic of structure (20b) above was synthesized according to the procedures disclosed in Example 2, and used in this experiment.

All inhibition assays were performed at room 15 temperature in 96 well microplates using Bio-Rad microplate reader (Model 3550). A 1 mM solution of structure (20b) in water served as the stock solution for all the inhibition assays. The hydrolysis of chromogenic substrates was monitored at 405 nm. The reaction progress 20 curves were recorded by reading the plates, typically 60 times with 30 second to 2 minute intervals. Initial rates were determined by unweighted nonlinear least-squares fitting to a first order reaction in GraFit (Erlhacus Software Limited, London, England). The determined 25 initial velocities were then nonlinear least-square fitted against the concentrations of structure (20b) using GraFit to obtain K_i . The general format of these assays are: 100 ml of a substrate solution and 100 ml of structure (20b) solution were added in a microplate well, then 50 ml 30 of enzyme solution was added to initiate the reaction. Typically, eight structure (20b) concentration points were employed for K_i determination. The values of K_i of structure (20b) against nine serine proteases are tabulated in Table 6.

Thrombin: N-p-tosyl-Gly-Pro-Arg-pNA (from Sigma) was used at 0.5 mM concentration in 1% DMSO (v/v) pH8.0 tris buffer (tris, 50 mM, TWEEN 20, 0.1%, BSA, 0.1%, NaCl, 0.15 M, CaCl₂, 5 mM) as substrate. From structure (20b) 5 stock solution two steps of dilution were made, first, 1:100 dilution in water, then 1:50 dilution in the pH8.0 tris buffer to serve as the first point (200 nM). Seven sequential dilutions were made from the first point for the assay.

10 Factor VII: S-2288 (from Pharmacia), D-Ile-Pro-Arg-pNA was used at 2.05 mM in the pH 8.0 tris buffer (see thrombin assay). From the stock of structure (20b), a 1:100 dilution was made in the tris buffer. From this concentration point seven more sequential dilutions were 15 made for the assay.

Factor X: Buffer and substrate were the same as used for thrombin assay. A 1:100 dilution was made in the pH8.0 tris buffer to serve as the first point. Seven more dilutions from the first were made for the assay.

20 Urokinase: Buffer, 50 mM tris, 50 mM NaCl, pH=8.8. S-2444 (from Sigma), pyroGlu-Gly-Arg-pNA at 0.25 mM in buffer was utilized as substrate. 1:10 dilution in buffer was made from the stock of structure (20b) as the first point, then seven more dilutions from the first 25 point were made for the assay.

Tissue Plasminogen Activator (t-PA): Buffer, substrate and the dilution scheme of structure (20b) were the same as utilized for Factor VII assay.

30 Activated Protein C (aPC): Buffer was the same as used in thrombin assay. 1.25 mM S-2366 in the assay buffer was utilized as substrate. Dilutions of structure (20b) were the same as in urokinase assay.

Plasmin: Buffer (see thrombin assay); S-2251 (from Pharmacia), D-Val-Leu-Lys-pNA at 1.25 mM in assay

buffer was utilized as substrate. For dilutions of structure (20b) (see urokinase assay).

Tryptase: 0.1 M tris, 0.2 M NaCl, 0.1 mg/ml heparin, pH=8.0 was utilized as buffer. 0.5 mM S-2366 5 (from Pharmacia), L-pyroGlu-Pro-Arg-pNA in buffer was used as substrate. From the 1 mM stock of structure (20b), 10 mM solution was made in water, then 1 mM solution was made in buffer from the 10 mM solution to serve as the first concentration point. From this point seven more dilutions 10 were made for the assay.

Trypsin: Buffer, substrate and the dilution scheme of structure (20b) were the same as used for thrombin.

15

Table 6


Enzyme	Source	K_i (nM)	
		Assay Conc. (nM)	Structure (20b)
thrombin	bovine plasma	2	0.66
factor VII	human	4	270
factor X	bovine plasma	8	966
urokinase	human kidney	3.7	600
t-PA	human	10	495
APC	human plasma	1	3320
plasmin	bovine plasma	4	415
tryptase	human lung	2	12.4
trypsin	bovine pancreas	5	0.64

As illustrated by the data presented in Table 6 above, structure (20b) functioned as a good thrombin 20 inhibitor, with good specificity against fibrinolytic enzymes.

Example 6Synthesis of Representative β -Sheet Mimetic

5

This example illustrates the synthesis of a representative β -sheet mimetic of this invention having the following structure (21):



10

Structure (21) was synthesized as follows. A solution of 48 mg (0.859 mmol) N^{α} -FMOC- N^{ϵ} -Cbz- α -ethanai-Lys-OMe [synthesized from N^{α} -Cbz-Lys-OMe by the same method used for the preparation of structure (5) from Phe-OMe], 15.9 mg (0.0859 mmol), Cys- OEt .HCl, and 13.2 μ L (0.0945 mmol) TEA were in 0.43 mL CH_2Cl_2 were stirred under Ar for 2 hr at room temperature. Bis(bis(trimethylsilyl)amino)tin(II) (39.8 μ L) was added and the reaction stirred overnight. The reaction solution was diluted with 10 mL EtOAc and washed with 6 mL each 10% citrate, water, and brine. The organic layer was dried over Na_2SO_4 , filtered, and concentrated. The resulting residue was purified by flash chromatography on silica gel using 40% EtOAc/hexanes to give, after drying in vacuo, 12.9 mg of colorless oil (23%) as a mixture of

diastereomers by ^1H NMR (CDCl_3). MS ES(+) m/z 658.2 (MH^+ , 30), 675.3 ($\text{M} + \text{Na}^+$, 100), 696.1 ($\text{M} + \text{K}^+$, 45).

5

Example 7

Synthesis of Representative β -Sheet Mimetic

This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

10

Synthesis of Structure (22):



15 Structure (22) was synthesized as follows. To a stirred solution of Cbz-Glu(OBn)-OH (5 g, 13.5 mmol) with DMAP (270 mg) and methanol (3 ml) in dichloromethane (100 ml) was added EDCI (3g) at 0°C. After stirring at 0°C for 3h, the solution was stirred at room temperature (rt) overnight. After concentration, the residue was taken up into EtOAc (100 ml) and 1N HCl (100 ml). The aqueous phase was separated and extracted with EtOAc (100 ml). The combined organic extracts were washed with sat. NaHCO_3 (100 ml), brine (100 ml), dried (MgSCl_2), passed through a short 20 pad of silica gel, and concentrated to provide 4.95 g an oil (95%). The product was pure enough to use for the next reaction without any further purification. ^1H NMR (CDCl_3) δ 2.00 (m, 1H), 2.25 (m, 1H), 2.50 (m, 2H), 3.74 (s, 3H, OCH_3), 4.42 (m, 1H, CHNH), 5.10 and 5.11 (two s, 4H, CH_2Ph), 5.40 (d, 1H, NH), 7.35 (s, 10H, phenyls); MS CI(isobutane) m/z 386 ($\text{M} + \text{H}^+$).

Synthesis of Structure (23):


5

Structure (23) was synthesized as follows: To a stirred solution of L-Glu-OH (4.41g, 30 mmol) with triethylamine (8.4 ml, 60 mmol) in 1,4-dioxane (40 ml) and H₂O (20 ml) was added Boc₂O (7 g, 32 mmol) at rt. After 10 stirring for 1.5h, the solution was acidified with 6N HCl (pH 2), and extracted with EtOAc (3x100 ml). The combined organic extracts were washed with H₂O (100 ml), brine (50 ml), dried (Na₂SO₄), and concentrated to provide an oil (9.5 g). Without further purification, the oil was used in 15 the next reaction.

A mixture of above oil (9.5 g) with paraformaldehyde (5 g) and p-TsOH·H₂O (400 mg) in 1,2-dichloroethane (200 ml) was heated at reflux with a Dean-Stark condenser, which was filled with molecular sieve 4A, 20 for 6h. After addition of EtOAc (100 ml) and sat. NaHCO₃ (50 ml), the solution was extracted with sat. NaHCO₃ (3x50 ml). The combined aqueous extracts were acidified with 6N HCl (pH 2), and extracted with EtOAc (3x100 ml). The combined organic extracts were washed with brine (100 ml), 25 dried (Na₂SO₄), and concentrated to provide an oil. The crude oil was purified by flash chromatography (hexane:EtOAc = 80:20 to 70:30 to 60:40) to provide an oil (4.04 g, 52%) which solidified slowly upon standing. ¹H NMR (CDCl₃) δ 1.49 (s, 9H, C(CH₃)₃), 2.18 (m, 1H, -CH₂CH₂), 2.29 (m, 1H, CH₂CH₂), 2.52 (m, 2H, -CH₂CH₂-), 4.33 (m, 1H, NHCHCH₂), 5.16 (d, 1H, J = 4.5 Hz, NCH₂O), 5.50 (br, 1H,

NCH_2O); ^{13}C NMR (CDCl_3) δ 25.85, 28.29, 29.33, 54.16, 79.10, 82.69, 152.47, 172.37, 178.13; MS (ES+) m/z 260 ($\text{M}+\text{H}^+$), 282 ($\text{M}+\text{Na}^+$), 298 ($\text{M}+\text{K}^+$).

5

Synthesis of Structure (24):


(24)

Structure (24) was synthesized as follows. To a 10 stirred solution of 1,1,1,3,3,3-hexamethyldisilazane (2.1 ml, 10 mmol) in THF (10 ml) was added n-BuLi (4 ml of 2.5M in hexane, 10 mmol) at 0°C. The resulting solution was stirred at the same temperature for 30 min. After cooling to -78°C, to this stirred solution was added a solution of 15 carboxylic acid (23) (1.02 g, 3.94 mmol) in THF (10 ml) followed by rinsings of the addition syringe with 5 ml THF. The resulting solution was stirred at -78°C for 1h, and PhCH_2Br (0.46 ml, 3.9 mmol) was added. After stirring at -30°C for 3h, to this solution was added 1N HCl (50 ml) 20 and the resulting solution was extracted with EtOAc (100 ml). The organic extract was washed with brine (50 ml), dried (Na_2SO_4), and concentrated to provide an oil. The crude product was purified by flash chromatography (hexane:EtOAc = 80:20 to 60:40 to 50:50) to provide a 25 foamy solid (1.35 g, 98%): ^1H NMR (CDCl_3) δ 1.55 and 1.63 (two s, 9H, ratio 1.5:1 by rotamer, $\text{OC}(\text{CH}_3)_3$), 2.2-2.4 (m, 3H, $-\text{CH}_2\text{CH}_2-$), 2.6-2.9 (set of m, 1H, $-\text{CH}_2\text{CH}_2-$), 3.04 (d, 1H, $J = 13.5\text{Hz}$, $-\text{CH}_2\text{Ph}$), 3.33 and 3.58 (two d, 1H, $J = 13\text{Hz}$, ratio 2:1, $-\text{CH}_2\text{Ph}$), 4.03 (two d, 1H, $J = 4\text{Hz}$, A of ABq,

$-\text{NCH}_2\text{O}-$), 4.96 (two d, 1H, J = 4Hz, B of ABq, $-\text{NCH}_2\text{O}-$); MS (ES-) m/z 348 ($\text{M}-\text{H}^+$).

Synthesis of Structure (25):

5




Synthesis of structure (25) was carried out as follows. To a stirred solution of carboxylic acid (24) (1.05 g, 3.0 mmol) in dry THF (5 ml) was added 1,1'-carbonyldiimidazole (500 mg, 3.1 mmol) at rt. The resulting solution was stirred at rt for 30 min. The solution of acyl imidazole was used for the next reaction without purification.

15 Meanwhile, to a stirred solution of 1,1,1,3,3,3-hexamethyldisilazane (1.6 ml, 7.5 mmol) in THF (5 ml) was added n-BuLi (3 ml of 2.5 M solution in hexane, 7.5 mmol) at 0°C. After stirring at the same temperature for 30 min, the solution was cooled to -78°C. To the stirred solution was added a solution of Cbz-Glu(OBn)-OMe (1.16 g, 3 mmol) in THF (5 ml) followed by rinsings of the addition syringe with 2 ml THF. The resulting solution was stirred at the same temperature for 15 min. To this stirred solution was added the above acyl imidazole in 3 ml THF. After 25 stirring 30 min. at -78°C, to this solution was added sat. NH_4Cl (50 ml) and extracted with EtOAc (2x75 ml). The combined organic extracts were washed with sat. NaHCO_3 (50 ml), brine (50 ml), dried (Na_2SO_4), passed through a short pad of silica gel, and concentrated to provide an oil. 30 The crude product was purified by flash chromatography

(hexane: EtOAc = 90:10 to 80:20 to 70:30 to 60:40) to provide an oil (1.48 g, 69%): MS (ES+) m/z 734.4 ($M+NH_4^+$).


Synthesis of Structure (26a):

5




(26a)

Structure (26a) was synthesized as follows. A stirred solution of above starting keto ester (25) (530 mg, 0.7mmol) in EtOH/AcOH (10/1 ml) was treated with 10% Pd/C (ca. 100 mg) under 20 atm pressure of H_2 for 2 days. After filtration through a short pad of Celite, the filtrate was concentrated and dissolved in EtOAc (50 ml). The solution was washed with 1N HCl (30 ml), sat. $NaHCO_3$ (30 ml), brine (30 ml), dried (Na_2SO_4), and concentrated to provide an oil. The crude product was purified by flash chromatography (hexane: EtOAc = 80:20 to 60:40 to 50:50 to 20:80 to 0:100) to provide a foamy solid (95 mg, 34%). TLC (EtOAc) R_f 0.68; NMR ($CDCl_3$) δ 1.38 (two s, 9H, $OC(CH_3)_3$), 1.63 (s, 1H), 1.75 (m, 2H), 2.05 (m, 5H), 2.1-2.3 (set of m, 1H), 3.00 (d, 1H, J = 14 Hz, CH_2Ph), 3.21 (d, 1H, J = 13.5 Hz, CH_2Ph), 3.74 (collapsed two s, 4H, OCH_3 and NCH), 4.53 (d, 1H, J = 9.5 Hz), 5.01 (br, 1H, NH); MS (ES+) m/z 403 ($M+H^+$), 425 ($M+Na^+$). Stereochemistry was assigned by 2D NMR.

Synthesis of Structure (27a):

(27a)

5 Structure (27a) was synthesized as follows. To a solution of 28 mg (0.070 mmol) of the bicyclic ester (26a) stirred in 1 ml THF at room temperature was added 0.14 ml 1.0 M aqueous lithium hydroxide solution. The mixture was stirred vigorously for 20 h then quenched with 10 5% aqueous citric acid (1 ml). The mixture was extracted with ethyl acetate (3 x 25 ml) then the combined extracts were washed with water and brine and dried over anhydrous sodium sulfate. Filtration and concentration of the filtrate under vacuum gave 26 mg of white foam, used 15 without further purification.


Synthesis of Structure (28a):

(28a)

Structure (28a) was synthesized as follows. The bicyclic acid (27a) (26 mg, 0.067 mmol), benzothiazolylarginol trifluoroacetic acid salt (structure (17) 61 mg, 0.083 mmol) EDC (21 mg, 0.11 mmol) and HOBT 5 hydrate (16 mg, 0.10 mmol) were dissolved in THF (5 ml) and diisopropylethylamine (0.34 ml, 1.9 mmol) was added. The mixture was stirred at room temperature for 15h then diluted with ethyl acetate and extracted sequentially with 5% aqueous citric acid, saturated aqueous sodium 10 bicarbonate, water and brine. The organic solution was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to 60 mg of a yellow glass. ¹H NMR analysis indicated a mixture of four diastereomeric amides. MS (ES+): m/z 898 (M + Na⁺).

15

Synthesis of Structure (29a):



(29a)


20 A β -sheet mimetic of structure (29a) was synthesized as follows. The crude hydroxybenzothiazole (28a) (60 mg, 0.068 mmol) was dissolved in CH₂Cl₂ (2 ml) and Dess-Martin periodinane (58 mg, 0.14 mmol) was added. The mixture was stirred at room temperature for 6h then 25 diluted with ethyl acetate and stirred vigorously with 10% aqueous sodium thiosulfate for 10 minutes. The organic

solution was separated and extracted with saturated aqueous sodium bicarbonate, water and brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded 42 mg of yellow 5 glass. ¹H NMR analysis indicated a mixture of two diastereomeric ketobenzothiazoles.

The ketobenzothiazole (42 mg, 0.048 mmol) was dissolved in 95% aqueous trifluoroacetic (0.95 ml) acid and thioanisole (0.05 ml) was added. The resulting dark 10 solution was stirred for 18 hours at room temperature then concentrated under vacuum to a dark brown gum. The gum was triturated with diethyl ether and centrifuged. The solution was removed and the solid remaining was triturated and collected as above two more times. The 15 yellow solid was dried in a vacuum desiccator for 2 hours then purified by HPLC to give 1.4 mg of the deprotected product. MS (ES+): 562.4 (M + H⁺). HPLC: (t_r=21.17 min.)

Synthesis of Structure (26b):

20



(26b)


Structure (26b) was synthesized as follows. A 25 stirred solution of above starting keto ester (25) (615 mg, 0.86 mmol) in MeOH/AcOH (10/1 ml) was treated with 10 % Pd/C (ca. 60 mg) under 20 atm pressure of H₂ for 3 days. After filtration through a short pad of Celite, the filtrate was concentrated to provide an oil. The crude 30 product was purified by flash chromatography (hexane : EtOAc = 80 : 20 to 60 : 40 to 50:50 to 0:100) to collect the

more polar fraction (50 mg). Rf 0.12 (hexane: EtOAc=60:40); MS (ES+) m/z 433 (M+H+).

Above oil was treated with p-TsOH·H₂O (5 mg) in 1,2-dichloroethane (10 ml) at reflux temperature for 2 days. After concentration, the oily product was purified by preparative TLC (hexane: EtOAc = 80:20 to 60:40) to give an oil (10 mg). TLC Rf 0.36 (hexane : EtOAc =60:40); ¹H NMR (CDCl₃) δ 1.43 (s, 9H), 1.66 (m, 3H), 1.89 (m, 3H), 2.14 (m, 1H), 2.75 (m, 1H), 2.98 (m, 1H, CHN), 3.72 (s, 10 3H, Me), 4.30 (m, 1H), 5.59 (d, 1H, NH), 7.1-7.3 (m, 5H, phenyl); MS CI(NH₃) 403.2 (M+H+). Stereochemistry was assigned by 2D NMR.

Synthesis of Structure (28b):

15



(28b)


Structure (28b) was synthesized as follows. To a solution of 12 mg (0.030 mmol) of the bicyclic ester 20 (26b) stirred in THF 1 ml at room temperature was added 0.060 ml 1.0 M aqueous lithium hydroxide solution. The mixture was stirred vigorously for 25h then quenched with 5% aqueous citric acid (1 ml). The mixture was extracted with ethyl acetate (3 x 25 ml) then the combined extracts 25 were washed with water and brine and dried over anhydrous

sodium sulfate. Filtration and concentration of the filtrate under vacuum gave 19 mg of white foam.

The foam, benzothiazolylarginol trifluoroacetic acid salt (30 mg, 0.041 mmol) EDC (10 mg, 0.052 mmol) and 5 HOBr hydrate (9 mg, 0.059 mmol) were dissolved in THF (2 ml) and diisopropylethylamine (0.026 ml, 0.15 mmol) was added. The mixture was stirred at room temperature for 30h then diluted with ethyl acetate and extracted sequentially with 5% aqueous citric acid, saturated 10 aqueous sodium bicarbonate, water and brine. The organic solution was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to 28 mg of a yellow glass. ¹H NMR analysis indicated a mixture of four diastereomeric amides. MS (ES+): m/z 898 (M + Na⁺).

15

Synthesis of Structure (29b):



20 Structure (29b) was synthesized as follows. The crude hydroxybenzothiazole (28b) (28 mg) was dissolved in CH₂Cl₂ (2 ml) and Dess-Martin periodinane (29 mg, 0.071 mmol) was added. The mixture was stirred at room temperature for 18h then diluted with ethyl acetate and 25 stirred vigorously with 10% aqueous sodium thiosulfate for 10 minutes. The organic solution was separated and extracted with saturated aqueous sodium bicarbonate, water

and brine then dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded 32 mg of yellow glass. ¹H NMR analysis indicated a mixture of two diastereomeric ketobenzothiazoles.

5 The ketobenzothiazole (32 mg) was dissolved in 95% aqueous trifluoroacetic (0.95 ml) acid and thioanisole (0.05 ml) was added. The resulting dark solution was stirred for 20 hours at room temperature then concentrated under vacuum to a dark brown gum. The gum was triturated 10 with diethyl ether and centrifuged. The solution was removed and the remaining solid was triturated and collected as above two more times. The yellow solid was dried in a vacuum desiccator for 2 hours then purified by HPLC to give 1.3 mg of the deprotected product. MS (FB+): 15 562.36 (M + H⁺); HPLC: t_R =21.51 min. (Gradient 0 to 90% 0.1% TFA in CH₃CN / 0.1% TFA in H₂O over 40 min.)

Example 8

Activity of Representative β -Sheet Mimetic

20 as a Protease Inhibitor

This example illustrates the ability of a further representative β -sheet mimetic of this invention to function as an inhibitor for thrombin, Factor VII, 25 Factor X, Factor XI, and trypsin. The β -sheet mimetics of structures (29a) and (29b) above were synthesized according to the procedures disclosed in Example 7, and used in this experiment.

The proteinase inhibitor assays were performed 30 as described in Example 5 except as described below for Factor XI. The results are presented in Table 7.

Factor XI. The same buffer was utilized in this assay as in the thrombin assay. 1 mM S-2366 (from Pharmacia), L-pyroGlu-Pro-Arg-pNA, solution in water was

used as substrate. From a 1mM stock solution of structure (29a) or (29b) in water, a 1:10 dilution was made in buffer. From this 100 μ M solution, seven serial 1:5 dilutions were made in buffer for assay.

5

Table 7

Enzymes	K_i (nM)	
	Structure (29a)	Structure (29b)
Thrombin	10.4	0.085
Trypsin	0.54	0.20
Factor VII	1800	-
Factor X	4600	17
Factor XI	391	-

Example 9

10 Activities of Representative β -Sheet Mimetics
as a Protease Inhibitor

This example illustrates the ability of further representative β -sheet mimetics of this invention to 15 function as an inhibitor for thrombin, Factor VII, Factor X, Factor XI, trypsin, aPC, plasmin, tPA, urokinase and trypsin. The β -sheet mimetics of structures (20) and (29b) above were synthesized according to the procedures disclosed in Examples 2 and 7, respectively, and used in 20 this experiment.

The proteinase inhibitor assays were performed as described in Example 5 except as described in Example 8 for Factor XI. The results are presented in Table 8.

Table 8

Structure (20b)		Structure (29b)		
Ki (nM)	Selectivity *	Ki (nM)	Selectivity *	
Thrombin	0.65	1	0.085	1
Trypsin	0.62	0.95	0.23	2.7
Factor VII	270	415	200	2353
Factor X	222	342	19.3	227
Factor XI	27.0	42	75.3	886
Tryptase	12.3	18.9	9.0	106
aPC	3320	5108	1250	14706
Plasmin	415	638	251	2953
tPA	495	762	92.9	1093
Urokinase	600	923	335	3941


*selectivity is the ratio of Ki of an enzyme to the Ki of thrombin

5

Example 10

Synthesis of Representative β -Sheet Mimetics


10 This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

Synthesis of Structure (30):

(30)

5


Structure (30) was synthesized as follows. n-Butyllithium (700 μ L, 1.75 mmol, 2.5M in hexanes) was added over 5 min to a solution of tris(methylthio)methane (256 μ L, 1.95 mmol) in THF (1 ml) at -78 °C. The mixture was stirred for 40 min then treated with a solution of bis-Boc-argininal (structure (16) from Example 2) (100 mg, 1.75 mmol) in 2 ml THF, dropwise, over a period of 5 min. After stirring for 1.5 h, the reaction was quenched with saturated NH₄Cl solution and allowed to warm to room temperature. The layers were separated and the aqueous layer extracted with EtOAc (3x), washed with brine (1x), dried (Na₂SO₄) and concentrated. Purification by flash chromatography (EtOAc:Hexane 1:4) yielded 93 mg (73%) of the orthothiomethyl ester (structure (30)) and 8 mg of recovered aldehyde (structure (16)). ¹H NMR (500 MHz, CDCl₃) δ 9.80 (s, 1H), 8.32 (t, J = 5.0 Hz, 1H), 6.54 (s, 1H), 5.23 (d, J = 9.0 Hz, 1H), 4.0 (m, 1H), 3.84 (s, 3H), 3.64 (br s, 1H), 3.36 (br s, 1H), 3.31 (m, 2H), 2.70 (s, 3H), 2.62 (s, 3H), 2.19 (s, 9H), 2.14 (s, 3H), 1.68-1.50 (m, 4H), 1.49 (s, 9H), 1.43 (s, 9H).

Synthesis of Structure (31):

(31)

5


Structure (31) was synthesized as follows. A mixture of 77 mg (0.11 mmol) of the orthothiomethyl ester (structure (30)), 117 mg (0.43 mmol) of mercuric chloride, 10 and 39 mg (0.18 mmol) of mercuric oxide in 2.5 ml of 12:1 methanol/water was stirred at rt for 4 h. The mixture was filtered through Celite and the residue washed with EtOAc (3x). The filtrate was diluted with water and extracted with EtOAc (3x). The organic layer was washed twice with 15 75% NH₄OAc/NH₄Cl, then with NH₄Cl and dried (Na₂SO₄). The solvent was removed in vacuo and the residue purified by flash chromatography (EtOAc/Hex, 1:3) to give 48 mg (72%) of the two diastereomers of structure (31) in a 1:2.7 ratio. ¹H NMR (500 MHz, CDCl₃) (major diastereomer) δ 9.80 (s, 1H), 8.33 (t, J = 5.0 Hz, 1H), 6.54 (s, 1H), 4.66 (d, J = 10.5 Hz, 1H), 4.08 (dd, J = 5.0, 2.0 Hz, 1H), 3.97 (m, 1H), 3.84 (s, 3H), 3.77 (s, 3H), 3.30 (m, 2H), 3.06 (d, J = 5.0 Hz, 1H), 2.70 (s, 3H), 2.63 (s, 3H), 2.14 (s, 3H), 1.68-1.50 (m, 4H), 1.49 (s, 9H), 1.40 (s, 9H); MS (ES+): 25 m/z 631.5 (M+H⁺).

Synthesis of Structure (32):

(32)

5


Structure (32) was synthesized as follows. A solution of 32 mg of the methyl ester (structure (31)) (0.051 mmol) in THF/water (4 ml, 1:3) was treated with 5 mg (0.119 mmol) of LiOH·H₂O. After stirring for 45 min, the reaction was diluted with 5% citric acid and extracted with ethyl acetate (3x). The combined extracts were washed with brine, dried over Na₂SO₄ and concentrated to give 30 mg (96%) of structure (32) as a white solid. The product was used without further purification. ¹H NMR 500 MHz, CDCl₃, δ 9.80 (br s, 1H), 8.29 (br s, 1H), 6.54 (s, 1H), 5.62 (br s, 1H), 4.08 (m, 1H), 3.82 (s, 3H), 3.27 (br s, 3H), 2.69 (s, 3H), 2.62 (s, 3H), 2.13 (s, 3H), 1.65-1.50 (m, 4H), 1.48 (s, 9H), 1.37 (s, 9H); MS (ES-) 20 m/z 615.5 (M-H⁺).

Synthesis of Structure (33):

(33)

5

Structure (33) was synthesized as follows. To a solution of the compound of structure (32) (29 mg, 0.047 mmol), HOBr (8 mg, 0.056 mmol) and EDC (11 mg, 0.056 mmol) in THF (5 ml), phenethylamine (7 ml, 0.056 mmol) was added followed by diisopropylethylamine (12 μ L, 0.071 mmol). The reaction mixture was stirred at rt overnight and diluted with 5% citric acid. The organic layer was separated and the aqueous phase extracted with EtOAc (3x). The combined extracts were washed with a saturated solution of NaHCO₃, brine, dried over Na₂SO₄, and filtered. After concentration the crude product was purified by chromatography (EtOAc/Hex, 1:1) to give 26 mg (77%) of structure (33) over two steps. ¹H NMR (500 MHz, CDCl₃) δ 9.84 (s, 1H), 8.34 (t, J = 5 Hz, 1H), 7.28 (m, 3H), 7.21 (m, 2 H), 7.04 (m, 1H), 6.55 (s, 1H), 5.16 (d, J = 8.5 Hz, 1H), 4.56 (d, J = 5 Hz, 1H), 4.11 (dd, J = 5.0, 3.0 Hz, 1H), 3.98 (m, 1H), 3.84 (s, 3H), 3.66 (m, 1H), 3.51 (m, 2H), 3.17 (m, 1H), 2.81 (t, J = 7.5 Hz, 2H), 2.71 (s, 3H), 2.65 (s, 3H), 2.14 (s, 3H), 1.68-1.52 (m, 4H), 1.49 (s, 9H), 1.39 (s, 9H); MS (FAB+) m/z 720.6 ($M+H^+$) (FAB-) m/z 718.5 ($M-H^-$).

Synthesis of Structure (34):

5


(34)

Structure (34) was synthesized as follows. To a solution of phenethylamide (structure (33), 25 mg, 0.035 mmol) in THF (5 ml) was added 18 mg of p-toluenesulfonic acid monohydrate (0.093 mmol). The reaction mixture was stirred at rt overnight to give a baseline spot by TLC. The solution was concentrated in vacuo, and the residue washed twice with ether removing excess pTsOH to give structure (34) as a yellowish-white solid, which was used without further purification. ^1H NMR (500 MHz, CDCl_3) was consistent with the expected product, however, individual peak assignment was difficult due to broadening. MS (ES+) m/z 520.4 ($\text{M}+\text{H}^+$).

Structure (34) was reacted with structure (9a) of Example 1 (in an analogous manner to the procedure described in Example 2 for the synthesis of structure (18)), followed by oxidation and deprotection (in an analogous manner as described with respect to the oxidation and deprotection of structures (18) and (19), respectively) to provide structure (35) as identified in Table 9 below.

Example 11Synthesis of Representative β -Sheet Mimetics

This example illustrates the synthesis of a
5 further representative β -sheet mimetic of this invention.

Synthesis of Structure (36):

10


(36)

Structure (36) was synthesized in an analogous fashion to compound (34) starting with benzylamine and 15 structure (32). ^1H NMR (500 MHz, CDCl_3) was consistent with the expected product, however, individual peak assignment was difficult due to broadening. MS (FAB+) m/z 506.4 ($\text{M}+\text{H}^+$).

Structure (36) was reacted with structure (9a) 20 of Example 1 (in an analogous manner to the procedure described in Example 2 for the synthesis of structure (18)), followed by oxidation and deprotection (in an analogous manner as described with respect to the oxidation and deprotection of structures (18) and (19), 25 respectively) to provide structure (37) as identified in Table 9 below.

Example 12Synthesis of Representative β -Sheet Mimetics

5 This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

Synthesis of Structure (38):

10

(38)

Structure (38) was synthesized in an analogous fashion to structure (34) starting with 15 p-chlorophenethylamine and structure (32). ^1H NMR (500 MHz, CDCl_3) was consistent with the expected product, individual peak assignment was difficult due to broadening. MS (ES+) m/z 554.5 ($\text{M}+\text{H}^+$).


Structure (38) was reacted with structure (9a) 20 of Example 1 (in an analogous manner to the procedure described in Example 2 for the synthesis of structure (18)), followed by oxidation and deprotection (in an analogous manner as described with respect to the oxidation and deprotection of structures (18) and (19), 25 respectively) to provide structure (39) as identified in Table 9 below.

Example 13Synthesis of Representative β -Sheet Mimetics

5

This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

10

Synthesis of Structure (40):

(40)

Structure (40) was synthesized in an analogous fashion to compound (34) using p-methoxyphenethylamine and structure (32). ^1H NMR (500 MHz, CDCl_3) was consistent with the expected product, however, individual assignment was difficult due to broadening. MS (ES+) m/z 550.5 ($\text{M}+\text{H}^+$).

Structure (40) was reacted with structure (9a) of Example 1 (in an analogous manner to the procedure described in Example 2 for the synthesis of structure (18)), followed by oxidation and deprotection (in an analogous manner as described with respect to the oxidation and deprotection of structures (18) and (19), respectively) to provide structure (41) as identified in Table 9 below.


Example 14Synthesis of Representative β -Sheet Mimetics

5

This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

Synthesis of Structure (42):

10




(42)

Structure (42) was prepared as follows. In a 10 ml round-bottomed flask were added CH_2Cl_2 (10 ml), methyl 2,3-dimethylaminopropionate dihydrochloride (19.9 mg, 0.103 mmol, 1.5 eq), and diisopropylethylamine (53 ml, 0.304 mmol, 4.4 eq). This suspension was stirred magnetically at room temperature for 1 h at which time was added the compound of structure (30) (50 mg, 0.068 mmol, 1 eq), mercury(II)chloride (82.4 mg, 0.304 mmol, 4.4 eq), and mercury(II)oxide (25.7 mg, 0.120 mmol, 1.7 eq). The resulting yellow suspension was stirred for 16.5 h during which time the suspension turned gray. The reaction was diluted with CH_2Cl_2 (50 ml), washed with saturated aqueous NH_4Cl (5 ml), saturated aqueous NaCl (5 ml) and dried over Na_2SO_4 . The cloudy suspension was filtered and the solvent removed in vacuo. The white solid was purified on

preparative thin-layer chromatography to produce the imidazoline structure (42) (25.3 mg, 52% yield) as a clear amorphous solid.: R_f 0.11 (10% MeOH/CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 9.82 (s, 0.6H, N'H, mixture of tautomers), 5 9.78 (s, 0.4H, N" H), 8.35 (dd, J=4.3, 11 Hz, ¹H, N-5), 6.54 (s, 1H, ArH), 5.08 (d, J=11 Hz, 1H, CHOH), 4.52 (m, 1H, imidazoline CH₂), 4.38 (d, J=21 Hz, 1H), 3.8-4.0 (m, 2H), 3.86 (s, 3H, CO₂CH₃), 3.767 (s, 3H, ArOCH₃), 3.5-3.7 (m, 2H, C-5 CH₂), 3.16-3.27 (m, C-5 CH₂), 2.70 (s, 3H, ArCH₃), 10 2.63 (s, 3H, ArCH₃), 2.14 (s, 3H, ArCH₃), 1.5-1.7 (m, 4H, C-3 and C-4 CH₂), 1.49 (s, 9H, Boc), 1.46 (s, 9H, Boc); IR (film) 1725.56, 1685.68, 1618.36, 1585.45, 1207.09, 1148.85 cm⁻¹; MS (ES+) m/e 699.4 (M+H⁺).

15

Synthesis of Structure (43):




(43)

20 Structure (43) was synthesized as follows. In a 25 ml round-bottomed flask was placed the compound of structure (42) (230 mg, 0.33 mmol), CHCl₃ (5 ml) and MnO₂ (500 mg, 5.75 mmol, 17.4 eq). After stirring for 5 h the suspension was filtered and the solid washed with 25 methanol. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate (5 ml) and methanol (1 ml) and a fresh portion of MnO₂ (500 mg) was introduced and the reaction stirred for 15 h at room temperature.

The solid was filtered and the solvent removed in vacuo. The residue was purified via column chromatography on silica gel, eluting with 1:1 ethyl acetate:hexane, then pure ethyl acetate, then 1:9 methanol:ethyl acetate to 5 obtain the desired product (structure (43), 190 mg, 83% yield) as an amorphous solid.: R_f 0.64 (70:30-ethyl acetate:hexane); ^1H NMR (500 MHz, CDCl_3) δ 10.70 (bs, 1H, imidazole NH), 9.70 (s, 1H), 8.28 (s, 1H), 7.84 (s, 1H), 6.54 (s, 1H, ArH), 5.35 (m, 1H, aH), 5.25 (s, 1H, BocNH), 10 3.926 (s, 3H), 3.840 (s, 3H), 3.15-3.40 (m, 2H), 2.682 (s, 3H), 2.133 (s, 3H), 1.52-1.70 (m, 4H), 1.470 (s, 9H), 1.424 (s, 9H); IR (film) 1724.68, 1619.03, 1277.72, 1151.93, 1120.61 cm^{-1} ; MS (ES+) m/e 695.2 ($\text{M}+\text{H}^+$, 22), 717.2 ($\text{M}+\text{Na}^+$, 100).

15

Synthesis of Structure (44):



Structure (44) was synthesized by the same 20 method used to construct structure (33) to structure (34). The product was used in the coupling without further purification.

Structure (44) was reacted with structure (9a) of Example 1 (in an analogous manner to the procedure 25 described in Example 2 for the synthesis of structure (18)), followed by deprotection (in an analogous manner as described with respect to the deprotection of structure (19) respectively) to provide structure (45) as identified

in Table 9 below. In the preparation of structure (45), the coupling step was performed with the carbonyl compound of structure (44), rather than with the analogous hydroxy compound.


5

Example 15

Synthesis of Representative β -Sheet Mimetics

10 This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

Synthesis of Structure (46):



15

Structure (46) was synthesized in an analogous fashion to structure (17) starting from structure (16) and thiazole. This compound was used in the coupling step without further purification.

20 Structure (46) was reacted with structure (9a) of Example 1 (in an analogous manner to the procedure described in Example 2 for the synthesis of structure (18)), followed by oxidation and deprotection (in an analogous manner as described with respect to the 25 oxidation and deprotection of structures (18) and (19), respectively) to provide structure (47) as identified in Table 9 below.


Example 16Synthesis of Representative β -Sheet Mimetics

5

This example illustrates the synthesis of a further representative β -sheet mimetic of this invention.

Synthesis of Structure (48):

10




To a solution of α -Boc- β -Fmoc-2,3-diaminopropionic acid (818 mg, 1.92 mmol) stirred in THF (5 ml) at -25°C was added 4-methyloxymorpholine (0.23 ml, 2.1 mmol) followed by isobutylichloroformate (0.25 ml, 1.9 mmol). The resulting suspension was stirred for 5 minutes and then filtered with the aid of 5 ml of THF. The filtrate was cooled in an ice/water bath then sodium borohydride (152 mg, 0.40 mmol) dissolved in water (2.5 ml) was added dropwise. The mixture was stirred for 15 minutes then water (50 ml) was added and the mixture was extracted with CH_2Cl_2 (3 x 50 ml). The combined extracts were washed with brine, dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded a pale yellow solid that was purified by

flash chromatography (50% ethyl acetate/hexanes eluent) to give 596 mg of the alcohol as a white solid.

The alcohol (224 mg, 0.543 mmol) was dissolved in methylene chloride and Dess-Martin periodinane (262 mg, 5 0.64 mmol) was added. The mixture was stirred at room temperature for 1 h then diluted with ethyl acetate (50 ml) and extracted sequentially with 10% aqueous $\text{Na}_2\text{S}_2\text{O}_3$, saturated aqueous NaHCO_3 , and brine. The organic solution was dried over anhydrous sodium sulfate, filtered and 10 concentrated under vacuum to a white solid. Purification of the solid by flash chromatography yielded 169 mg of the aldehyde structure (48) as a white solid.


Synthesis of Structure (49):

15



Structure (49) was synthesized in an analogous fashion to structure (17) starting from structure (48) and 20 benzothiazole. This compound was used as a 1:1 mixture of diastereomers in the coupling step (described below) without further purification. MS (EI⁺): m/z 446.4 (M+H⁺).

Synthesis of Structure (50):



5 Structure (49) and bicyclic acid structure (9a)
 (27 mg, 0.069 mmol) and HOBr hydrate (71 mg, 0.46 mmol)
 were dissolved in THF (1 ml) and diisopropylethylamine
 (0.059 ml, 0.34 mmol) was added followed by EDC (19 mg,
 0.099 mmol). The mixture was stirred at room temperature
 10 for 20 h then diluted with ethyl acetate and extracted
 sequentially with 5% aqueous citric acid, saturated
 aqueous sodium bicarbonate, water and brine. The organic
 solution was dried over anhydrous sodium sulfate, filtered
 and concentrated under vacuum to 61 mg of a yellow foam.
 15 ^1H NMR analysis indicated a mixture of diastereomeric
 amides.

The foam was dissolved in CH₃CN and diethylamine was added. The solution was stirred at room temperature for 30 minutes then concentrated under vacuum to a yellow foam. The foam was rinsed with hexanes and dissolved in DMF (0.5 ml). In a separate flask, carbonyldiimidazole (16 mg, 0.99 mmol) and guanidine hydrochloride (10 mg, 0.10 mmol) were dissolved in DMF (1 ml) and diisopropylethylamine (0.035 ml, 0.20 mmol) was added followed by DMAP (1 mg). The solution was stirred for 1.5 h at room temperature then the solution of amine was added

and stirring was continued for 16 h. The solution was concentrated under vacuum then water was added to the residue and the mixture was extracted with ethyl acetate (3 x 25 ml). The combined extracts were washed with 5 brine, dried over anhydrous sodium sulfate and filtered. Concentration of the filtrate under vacuum yielded 58 mg of structure (50) as a yellow foam. MS (ES+): m/z 680.6 ($M+H^+$).

Structure (50) was oxidized to provide the 10 corresponding ketone of structure (51).

Example 17


Activities of Representative β -Sheet Mimetics
as a Protease Inhibitor

15

This example illustrates the ability of further representative β -sheet mimetics of this invention to function as an inhibitor for thrombin, Factor VII, Factor X, Factor XI, trypsin, aPC, plasmin, tPA, urokinase 20 thrombin thrombomodulin complex and trypsin. The β -sheet mimetics of the structures listed in Table 9 had the inhibition activities shown in Table 10.

The proteinase inhibitor assays were performed as described in Example 9. The assay for thrombin-25 thrombomodulin complex was conducted as for thrombin except that prior to the addition of inhibitor and substrate, thrombin was preincubated with 4 nM thrombomodulin for 20 minutes at room temperature.

Table 9
Structures, Synthetic Precursors, and Physical Data for
Various Serine Protease Inhibitors



Struc- ture Number	β^6	R_4	R_5	Precursor	M.S. (ES ⁺)	HPLC R.T. (min)
(47)	N			(46)	513.5 (M+H ⁺)	15.9
(20b)	N			(17)	563.5 (M+H ⁺)	17.9
(37)	N			(36)	563.6 (M+H ⁺)	16.9
(39)	N			(38)	511.3 (M+H ⁺)	19.8
(29a) ^a	CH			(27)	562.4 (M+H ⁺)	21.2

Struc- ture Number	B ^b	R ₄	R ₅	Precursor	M.S. (ES ⁺)	HPLC ^c R.T. (min)
(35)	N			(34)	577.4 (M+H ⁺)	18.1
(45)	N			(44)	554.2 (M+H ⁺)	15.7
(51)	N			(49)	578.3 (M+H ⁺)	22.3
(29b)	CH			(17)	FAB 562.4 (M+H ⁺)	21.5
(41)	N			(40)	607.4 (M+H ⁺)	18.2
(13)	N			Arg(Mtr)-CH ₂ Cl	477.9 (M+H ⁺)	14.9

^aThe stereochemistry of the template for B = CH is

(3R, 6R, 9S) except where noted (see footnote e).

^bTemplate stereochemistry is (3S, 6R, 9S).

^cHPLC was performed on a reverse phase C-18 column 5 using a gradient of 0-90% acetonitrile/water, 0.1% TFA.

Table 10
Ki (M) Inhibition Activity of Various Compounds Against Serine Proteases

Structure Number	Thrombin Factor VII	Factor X Factor XI	Urokinase	T.T.C. ^a	αPC ^b	Plasmin	tPA ^c	Trypsin	Trypsinase
35	7.10E-11	1.64E-08	1.45E-07 ^e					2.70E-11	
37	7.32E-11							7.73E-11	
29L	8.50E-11	2.00E-07	1.91E-08	7.53E-08	3.35E-07	8.80E-11	1.25E-06	2.51E-07	9.29E-08
39	3.10E-10								
41	4.50E-10								
20b	6.50E-10	2.70E-07	2.22E-07	2.70E-08	6.00E-07	3.32E-06	4.15E-07	4.95E-07	6.20E-10
47	2.40E-09	9.68E-07	1.50E-06 ^e					1.90E-09	
45	5.40E-09	2.96E-05	3.80E-05	1.24E-06	6.90E-09	2.56E-05	2.38E-05	1.72E-05	5.24E-08
51	7.25E-09	4.26E-06	5.70E-05	1.73E-06				3.79E-08	
29a	1.04E-08	1.77E-06	4.65E-06 ^e	1.91E-07				5.40E-10	
13 ^d	1.20E-09	1.40E-07	3.86E-07 ^e		9.27E-07	5.28E-07	9.7AE-07	6.32E-07	1.60E-07

^a Thrombin thrombomodulin complex, ^b activated Protein C, ^c tissue Plasminogen Activator, ^d IC50, ^e bovine plasma


5

Example 18Effect of Representative β -Sheet Mimetics on Platelet Deposition in a Vascular Graft

5 The effect of compounds of the invention on platelet deposition in a vascular graft was measured according to the procedure of Hanson et al. "Interruption of acute platelet-dependent thrombosis by synthetic antithrombin 10 D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone" Proc. Natl. Acad. Sci., USA 85:3148-3188, (1988), except that the compound was introduced proximal to the shunt as described in Kelly et al., Proc. Natl. Acad. Sci., USA 89:6040-6044 (1992). The results are shown in Figures 1, 2 and 3 for structures (20b), (39) 15 and (29b), respectively.

Example 19Synthesis of Representative β -Sheet Mimetics


20 This example illustrates the synthesis of a further representative β -sheet mimetic of this invention having the structure shown below.



(52)


25

Structure (52) may be synthesized employing the following intermediate (53) in place of intermediate (16) in Example 2:




(53)

Intermediate (53) may be synthesized by the
5 following reaction scheme:



Alternatively, intermediate (53) may be
10 synthesized by the following reaction scheme:

124




From the foregoing, it will be appreciated that, although specific embodiments of this invention have been described herein for purposes of illustration, various 5 modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except by the appended claims.

Claims


What is claimed is:

1. A β -sheet mimetic including a bicyclic ring system, said β -sheet mimetic having the structure:




wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; A is selected from -C(=O)-, -(CH₂)₁₋₄-, -C(=O)(CH₂)₁₋₃-, -(CH₂)₁₋₂O- and -(CH₂)₁₋₂S-; B is selected from N and CH; C is selected from -C(=O)-, -(CH₂)₁₋₃-, -O-, -S-, -O-(CH₂)₁₋₂- and -S(CH₂)₁₋₂-; Y and Z represent the remainder of the molecule; and any two adjacent CH groups of the bicyclic ring may form a double bond; with the provisos that (i) R₁ is an amino acid side chain moiety or derivative thereof other than hydrogen, (ii) when R₁ is benzyl, R₂ and R₃ are both hydrogen, A is -CH₂CH₂- and B is CH, then C is not -CH₂-; (iii) when R₁ is methyl, R₂ and R₃ are both hydrogen, A is -CH₂O- and B is CH, then C is not -CH₂-; and (iv) when R₁ is benzyl, R₂ and R₃ are both hydrogen, A is -CH₂- and B is CH, then C is not -S-.

2. The β -sheet mimetic of claim 1 having the structure:




wherein A is selected from $-\text{C}(=\text{O})-$, $-(\text{CH}_2)_{1-4}-$ and $-\text{C}(=\text{O})(\text{CH}_2)_{1-3}-$; C is selected from $-\text{C}(=\text{O})-$ and $-(\text{CH}_2)_{1-3}$ and the bicyclic ring system is saturated.

3. The β -sheet mimetic of claim 2 having the structure:




wherein n is an integer from 1 to 4 and p is an integer from 1 to 3.

4. The β -sheet mimetic of claim 2 having the structure:




wherein p is an integer from 1 to 3.

5. The β -sheet mimetic of claim 2 having the structure:




wherein n is an integer from 1 to 4.

6. The β -sheet mimetic of claim 2 having the structure:




wherein n is an integer from 1 to 4 and p is an integer from 1 to 3.

7. The β -sheet mimetic of claim 2 having the structure:




wherein p is an integer from 1 to 3.

8. The β -sheet mimetic of claim 2 having the structure:




wherein n is an integer from 1 to 4.


9. The β -sheet mimetic of claim 2 having the structure:



10. The β -sheet mimetic of claim 2 having the structure:




11. The β -sheet mimetic of claim 2 having the structure:




wherein n is an integer from 1 to 4.

12. The β -sheet mimetic of claim 11 wherein n is 2 and R₂ is hydrogen.

13. The β -sheet mimetic of claim 12 having the structure:




14. The β -sheet mimetic of claim 12 having the structure:




130


15. The β -sheet mimetic of claim 12 having the structure:




16. The β -sheet mimetic of claim 12 having the structure:




17. The β -sheet mimetic of claim 12 having the structure:




18. The β -sheet mimetic of claim 12 having the structure:




19. The β -sheet mimetic of claim 12 having the structure:




20. The β -sheet mimetic of claim 12 having the structure:



21. The β -sheet mimetic of claim 12 having the structure:




22. The β -sheet mimetic of claim 1 having the structure:




wherein A is selected from $-(CH_2)_{1-4}$, $-(CH_2)_{1-2}O-$ and $-(CH_2)_{1-2}S-$; C is selected from $-(CH_2)_{1-3}$, $-O-$, $-S-$, $-O(CH_2)_{1-2}-$ and $-S(CH_2)_{1-2}-$, and the bicyclic ring system is saturated.

23. The β -sheet mimetic of claim 22 having the structure:




wherein n is an integer from 1 to 4.

24. The β -sheet mimetic of claim 22 having the structure:




wherein m is an integer from 1 to 2; and p is an integer from 1 to 3.

25. The β -sheet mimetic of claim 22 having the structure:




wherein m is an integer from 1 to 2; and p is an integer from 1 to 3.

26. The β -sheet mimetic of claim 22 having the structure:




wherein p is an integer from 1 to 3.

27. The β -sheet mimetic of claim 22 having the structure:




wherein p is an integer from 1 to 3.

28. The β -sheet mimetic of claim 22 having the structure:




wherein p is an integer for 1 to 3; and m is an integer from 1 to 2.

29. The β -sheet mimetic of claim 22 having the structure:



wherein p is an integer for 1 to 3; and m is an integer from 1 to 2.


30. The β -sheet mimetic of claim 22 having the structure:




wherein p is an integer from 1 to 3.

31. The β -sheet mimetic of claim 30 wherein A is $-\text{CH}_2\text{CH}_2-$, p is 1 and R_2 and R_3 are both hydrogen.


32. The β -sheet mimetic of claim 31 having the structure:



33: The β -sheet mimetic of claim 31 having the structure:




34. The β -sheet mimetic of claim 31 having the structure:



35. The β -sheet mimetic of claim 1 wherein Y and Z are each at least one amino acid.

36. The β -sheet mimetic of claim 35 wherein R₁, R₂, R₃, A, B and C are as defined in any one of claims 3 through 14 and 16 through 33.

37. A method for inhibiting a protease in a warm-blooded animal, comprising administering to the animal an effective amount of a β -sheet mimetic having the structure:



wherein R₁, R₂ and R₃ are independently selected from amino acid side chain moieties and derivatives thereof; A is selected from -C(=O)-, -(CH₂)₁₋₄-, -C(=O)(CH₂)₁₋₃-, -(CH₂)₁₋₂O- and -(CH₂)₁₋₂S-; B is selected from N and CH; C is selected from -C(=O)-, -(CH₂)₁₋₃-, -O-, -S-, -O-(CH₂)₁₋₂- and -S(CH₂)₁₋₂-; Y and Z represent the remainder of the molecule; and any two adjacent CH groups of the bicyclic ring may form a double bond; with the provisos that (i) R₁ is an amino acid side chain moiety or derivative thereof other than hydrogen, (ii) when R₁

is benzyl, R₂ and R₃ are both hydrogen, A is -CH₂CH₂- and B is CH, then C is not -CH₂-, (iii) when R₁ is methyl, R₂ and R₃ are both hydrogen, A is -CH₂O- and B is CH, then C is not -CH₂-, and (iv) when R₁ is benzyl, R₂ and R₃ are both hydrogen, A is -CH₂- and B is CH, then C is not -S-.

38. The method of claim 37 wherein the protease is a serine protease.

39. The method of claim 38 wherein the serine protease is selected from thrombin, elastase and Factor X.

40. The method of claim 38 wherein the serine protease is thrombin.

41. The method of claim 37 wherein the β -sheet mimetic is the β -sheet mimetic of claim 13.

42. The method of claim 37 wherein the β -sheet mimetic is the β -sheet mimetic of claim 17.

43. The method of claim 37 wherein the β -sheet mimetic is the β -sheet mimetic of claim 32.

44. The method of claim 37 wherein the β -sheet mimetic is the β -sheet mimetic of claim 33.

45. The method of claim 37 wherein the β -sheet mimetic is the β -sheet mimetic of claim 34.

46. The method of claim 37 wherein the protease is selected from an aspartic, cysteine and metallo protease.

1/3




Fig. 1

2/3




Fig. 2

3/3




Fig. 3

INTERNATIONAL SEARCH REPORT

by **Patent Application No**
PCT/US 96/04115

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C07K5/06	C07K5/08	C07K5/10	C07K5/02	A61K38/04
--------------	-----------------	-----------------	-----------------	-----------------	------------------

According to International Patent Classification (IPC) or to both national classifications and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 49, no. 17, 23 April 1993, OXFORD GB, pages 3577-3592, XP0020008589 U NAGAI ET AL.: "Bicyclic turned dipeptide (BTD) as a beta-turn mimetic; its design, synthesis and incorporation into bioactive peptides" see the whole document</p> <p>---</p> <p style="text-align: center;">-/-</p>	1-46

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'B' earlier documents but published on or after the international filing date
- *'C' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another claim or other special reasons (as specified)
- *'D' document referring to an oral disclosure, use, exhibition or other means
- *'E' document published prior to the international filing date but later than the priority date claimed

*'F' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*'G' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*'H' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*'I' document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

16 July 1996

29.07.96

Name and mailing address of the ISA

European Patent Office, P.B. 3018 Rotterdam 3
NL - 2200 HV Rijswijk
Tel. (+31-70) 300-2000, Tx. 31 651 opo nl
Fax: (+31-70) 340-2016

Authorized officer

Masturzo, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/04115**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 37-46 refer to a method of treatment of the human body. The search was carried out and based on the alleged effects of the products.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protests

The additional search fees were accompanied by the applicant's protests.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

SEARCH APPLICATION NO
PCT/US 96/04115

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.
A	<p>TETRAHEDRON LETTERS, vol. 36, no. 4, 23 January 1995, OXFORD GB, pages 625-628, XP002008590 L COLOMBO ET AL.: "Conformationally constrained dipeptides; synthesis of 7,5 and 6,5-fused bicyclic lactams by stereoselective radical cyclization" see the whole document ---</p>	1-15
P,X	<p>JOURNAL OF ORGANIC CHEMISTRY, vol. 61, no. 4, 23 February 1996, EASTON US, pages 1198-1204, XP002008591 U SLOMCZYNSKA ET AL.: "Electrochemical cyclization of dipeptides to form novel bicyclic, reverse turn peptidomimetics. 2. Synthesis and conformational analysis of 6,5-bicyclic systems" see the whole document ---</p>	1-46
A	<p>CHEMICAL ABSTRACTS, vol. 117, no. 13, 28 September 1992 Columbus, Ohio, US; abstract no. 131548s, J E BALDWIN ET AL.: "Synthesis of a bicyclic gamma-lactam dipeptide analog" page 786; XP002008592 see abstract & HETEROCYCLES, vol. 34, no. 5, May 1992, AMSTERDAM NL. pages 903-906. -----</p>	1-46